1. Introduction {#sec0005}
===============

Equine arteritis virus (EAV) was first isolated from the lung of an aborted fetus following an extensive outbreak of respiratory disease and abortion on a Standardbred breeding farm near Bucyrus, Ohio, USA, in 1953 ([@bib0335], [@bib0345]). After isolation of the causative virus and description of characteristic vascular lesions, equine viral arteritis (EVA) was identified as an etiologically distinct disease of the horse ([@bib0335]). EAV is a small enveloped, positive-sense, single-stranded RNA virus that is the prototype virus in the family *Arteriviridae* (genus: *Arterivirus*), order *Nidovirales*, a taxonomic grouping that includes porcine reproductive and respiratory syndrome virus (PRRSV), simian hemorrhagic fever virus (SHFV), and lactate dehydrogenase-elevating virus (LDV) of mice ([@bib0185]). Pioneering work on the distinctive replication strategy utilized by EAV originally led to the taxonomic designation of the Order *Nidovirales* ([@bib0185]), a grouping of morphologically distinct viruses included in the families *Arterviridae*, *Coronaviridae*, and *Roniviridae* that all utilize a similar replication strategy that involves the generation of a nested set of subgenomic RNAs ([@bib0285], [@bib0310], [@bib0505], [@bib1045]). The order *Nidovirales* has been expanded recently to include several newly identified plus-stranded RNA viruses including wobbly possum disease virus (WPDV), a close relative to the other members of the family *Arteriviridae* and the cause of neurologic disease among free-ranging Australian brushtail possums (*Trichosurus vulpecula*) in New Zealand ([@bib0355]). Similarly, two new genetically divergent SHFV variants (SHFV-krc1 and SHFV-krc2) were recently identified in a single male colobus monkey (*Procolobus rufomitratus tephrosceles*; [@bib0680]). Both SHFV-krc1 and SHFV-krc2 are highly divergent from the prototypic LVR 42-0/6941 strain of SHFV (52.0% and 58.1% nucleotide diversity, respectively) and, interestingly, the two variants are also significantly different from one another and share only 51.9% nucleotide sequence identity. Subsequently, two additional highly divergent variants of SHFV (SHFV-krtg-1a/b and SHFV-krtg-2a/b \[79.4% nucleotide identity\]) were isolated from African red-tailed (guenon) monkeys (*Cercopithecus ascanius*) from Kibale National Park, Uganda ([@bib0685]). These two variants were also genetically distinct from the prototypic LVR 42-0/6941 strain of SHFV (54.1%) and the SHFV-krc1 and SHFV-krc2 (50.1%) variants. Additional novel nidoviruses have also been isolated recently from mosquitoes, including Cavally virus (CAVV) and Nam Dinah virus (NDiV). These newly identified arthropod-borne nidoviruses are provisionally placed in a new family *Mesoniviridae*, which is an intermediate between the families *Arteriviridae* and *Coronaviridae* and more closely related to the family *Roniviridae* ([@bib0675]). The recent recognition of these related but distinct viruses that share similar replication strategies indicates an increasing need for reclassification of the order *Nidovirales*.

Like the other arteriviruses, EAV infection is highly species-specific and exclusively limited to members of the family *Equidae*, which includes horses, donkeys, mules, and zebras ([@bib1105], [@bib1215]). The EAV associated disease, EVA, is a respiratory and reproductive disease of horses that occurs worldwide ([@bib0130], [@bib0455], [@bib1215]). Although there is only one known EAV serotype, field strains of the virus differ in their virulence and neutralization phenotype ([@bib0100], [@bib0055], [@bib0095], [@bib0070], [@bib0475], [@bib0730], [@bib0805], [@bib0910], [@bib0950], [@bib1245], [@bib1430], [@bib1410]). The clinical signs exhibited by individual EAV-infected horses depend on a variety of factors including the age and physical condition of the animal, challenge dose and route of infection, strain of virus, and environmental factors. With the sole and notable exception of the experimentally derived and highly horse-adapted, virulent Bucyrus strain, other strains and field isolates of EAV very rarely cause fatal infection in adult horses ([@bib0800], [@bib0950]). The vast majority of EAV infections are subclinical, but acutely infected animals may develop a wide range of clinical signs including pyrexia, depression, anorexia, dependent edema (scrotum, ventral trunk, and limbs), stiffness of gait, conjunctivitis, lacrimation and swelling around the eyes (periorbital and supraorbital edema), respiratory distress, urticaria, and leukopenia ([@bib1215]). The incubation period of 3--14 days (typically 6--8 days following venereal exposure) is followed by pyrexia of up to 41 °C (105.8 °F) that may persist for 2--9 days. The virus can cause abortion of pregnant mares, with abortion rates during field outbreaks varying from approximately 10% to 70%, depending on the virus strain ([@bib1215]). EAV-induced abortions can occur at any time between 3 and 10 months of gestation. Infection of neonatal foals can cause a severe fulminating interstitial pneumonia, and in 1--3 months old foals a progressive "pneumo-enteric" syndrome ([@bib1240]). A variable proportion of acutely infected stallions (10--70%) become persistently infected and shed the virus exclusively in their semen ([@bib1215] and references therein). There is no evidence of EAV causing persistent infection in mares, geldings, or foals. The virus persists mainly in the ampulla of the stallion\'s reproductive tract, and the establishment and maintenance of the carrier state in the stallion is testosterone-dependent.

Serologic surveys have shown that EAV infection has occurred among horses in North and South America, Europe, Australia, Africa, and Asia ([@bib0365], [@bib0370], [@bib1165], [@bib1215]). Other countries such as Iceland and Japan are apparently free of the virus. Recent studies have shown that New Zealand is also free of active EAV infection ([@bib0815]). However, the seroprevalence of EAV infection of horses varies between countries and among horse breeds within a country. For example, the seroprevalence of EAV infection varies among horses of different breeds and ages in the United States (US), with marked disparity between the prevalence of infection of Standardbred and Thoroughbred horses ([@bib1215]). EAV infection is considered endemic in Standardbred but not Thoroughbred horses in the US, with 77.5% to 84.3% of all Standardbreds but only up to 5.4% of Thoroughbreds being seropositive to the virus ([@bib0600], [@bib0780], [@bib0810], [@bib0820], [@bib0855], [@bib1210], [@bib1215]). Similarly, the seroprevalence of EAV infection of Standardbred horses in California was 68.5% in 1991, *versus* less than 2% in all other breeds tested ([@bib0810]). The 1998 National Animal Health Monitoring System (NAHMS) equine survey showed that only 0.6% of the US American Quarter Horse (AQH) population was seropositive to EAV ([@bib0010]). However, the extensive US outbreak of EVA in 2006--2007 mainly involved AQHs and this very likely significantly increased the seroprevalence of EAV within this breed. The seroprevalence of EAV infection of Warmblood stallions is also very high in a number of European countries, with some 55 to 93% of Austrian Warmblood stallions being seropositive to EAV ([@bib0170]). Similarly, there is high seroprevalence among mares and stallions of Hucul horses in Poland, 53.2% and 68.2%, respectively ([@bib0965]).

Transmission of EAV between horses occurs *via* either the respiratory or venereal route ([@bib0235], [@bib0345], [@bib0790], [@bib1215], [@bib1225], [@bib1220]). Horizontal respiratory transmission occurs after aerosolization of infected respiratory tract secretions from acutely infected horses; high titers of EAV are present in respiratory secretions for some 7--14 days during acute infection ([@bib0790]). However, direct and close contact is necessary for aerosol transmission of EAV between horses ([@bib0240], [@bib1210]). EAV can also be transmitted by aerosol from urine and other body secretions of acutely infected horses, aborted fetuses and their membranes, and the masturbates of acutely or chronically infected stallions ([@bib0170], [@bib0455], [@bib0460], [@bib0535], [@bib0770], [@bib0790], [@bib0795]). Venereal transmission of EAV contained in the semen of stallions that are either acutely or chronically infected with the virus is an especially important route of natural transmission of the virus ([@bib1225], [@bib1220]). Recently, it has been demonstrated that EAV can be experimental transmitted to naïve recipient mares *via* embryo transfer from a donor mare inseminated with EAV-infective semen to a naïve recipient mare ([@bib0155]).

2. Virion structure {#sec0010}
===================

The virion of EAV is spherical with a diameter of 40--60 nm and consists of a genome-containing nucleocapsid core (25--35 nm in diameter) composed of nucleocapsid (N) protein that is surrounded by a relatively smooth lipid envelope containing several membrane proteins ([@bib0320], [@bib0595], [@bib0745]). The envelope lacks large surface projections ([Fig. 1](#fig0005){ref-type="fig"} ). The EAV N protein appears to be organized as dimers of dimers (*i.e.* tetramers), which may reflect the arrangement of the protein in the viral nucleocapsid. The dimeric N-protein structure is similar to the previously determined structure of the N protein of PRRSV. Recent cryo-electron tomographic studies suggest that the core of the PRRSV virion is composed of a double-layered chain of N proteins bundled into a hollow ball with an asymmetric, linear arrangement, rather than the isometric core that was previously described ([@bib1085], [@bib0330]). The structural proteins of the EAV virion include seven envelope proteins (E, GP2, GP3, GP4, ORF5a protein, GP5, and M) and the N protein, which respectively are encoded by ORFs 2a, 2b, 3--4, 5a, 5b, and 6--7 that are located at the 3′ proximal quarter of the genome ([Fig. 2](#fig0010){ref-type="fig"} ; [@bib0265], [@bib0390], [@bib1025], [@bib1055], [@bib1390]). These structural proteins are expressed from six subgenomic viral messenger RNAs (sg mRNAs) that form a 3′-co-terminal nested set and contain a common leader sequence encoded by the 5′-end of the genome ([Fig. 2](#fig0010){ref-type="fig"} and [Table 1](#tbl0005){ref-type="table"} ; [@bib0305]).Fig. 1Equine arteritis virus particle: (a) electron micrograph of EAV (adapted from Snijder et al., Chapter 20, Topley & Wilson\'s Microbiology and Microbial Infections. London, UK with permission), (b) schematic presentation of EAV particle.Fig. 2The genome organization and polycistronic nature of the EAV genome. The genomic open reading frames (ORFs) are indicated and the names of the corresponding proteins are depicted. The pink boxes represent the body transcription regulatory sequences (TRSs). The nested set of mRNAs that is found in infected cells is depicted below the genome, with RNA1 being identical to the viral genome and sg mRNAs 2--7 being used to express the structural protein genes located in the 3′-proximal quarter of the genome. The light blue box at the 5′ end of each sg mRNA represents the common leader sequence, which is derived from the 5′ end of the genome. With the exception of the bicistronic sg mRNAs 2 and 5, the sg mRNAs are functionally monocistronic. Translation of proteins from sg mRNAs 2 (E and GP2 proteins) and 5 (ORF5a protein and GP5) occurs by leaky scanning of the 5′-proximal end of these sg mRNAs ([@bib0390], [@bib1055]). The ORFs 1a and 1b located at the 5′ end of the genome and are translated into two polyproteins (pp1a and pp1ab) that are further processed into 12--13 nonstructural proteins by three viral proteases (nsps 1, 2, and 4).Table 1Nonstructural and structural proteins of EAV.[a](#tblfn0005){ref-type="table-fn"}ORFProteinNucleotide position (bp)Protein length (aa)Predicted M.W. (kDa)ORF1a1a polyprotein225--53991725190ORF1b--5405--9751----  ORF1ab1ab polyprotein225--97513176349.3nsp1255--100426028.6nsp21005--271757161.4nsp32718--341623325nsp43417--402820421nsp54029--451416218.1nsp64515--4580222.3nsp74581--525522525.2nsp85256--5405505.5nsp95256--733369376.8nsp107334--873446750.5nsp118735--939121924.2nsp129392--974811912.5  ORF2aE9751--9954677.4ORF2bGP29824--10,50722725.0ORF3GP310,306--10,79716317.9ORF4GP410,700--11,15814215.6ORF5aORF5a11,112--11,291596.5ORF5bGP511,146--11,91325528.0ORF6M11,901--12,38916217.8ORF7N12,313--12,64511012.1[^2]

The non-glycosylated membrane protein M and glycosylated GP5 protein are the most abundant envelope proteins, and these major envelope proteins are presented as disulfide-linked heterodimers in virus particles. The envelope (E) protein is the third most abundant protein in the viral membrane ([@bib1055]). The GP2, GP3, and GP4 proteins are minor envelope glycoproteins that exist in equimolar amounts in virus particles ([@bib0265], [@bib1380]). The minor envelope glycoproteins are covalently associated and form a heterotrimeric complex on the surface of the virion ([@bib1380], [@bib1375], [@bib1385], [@bib1390]). The major envelope proteins (GP5 and M) and the N protein are essential for EAV particle formation, whereas neither E protein nor the minor envelope proteins are required for production of viral particles since absence of any of these proteins does not inhibit incorporation of viral genomic RNA or change buoyant density or microscopic appearance of the virus ([@bib0840]). In contrast, with the exception of the ORF5a protein, all major (N, GP5, and M) and minor (E, GP2, GP3, and GP4) structural proteins are required for production of infectious progeny virus, as shown by individually knocking out the expression of each structural protein ([@bib1390]). Furthermore, it has been shown by reverse genetic studies that elimination of ORF5a protein expression cripples EAV, leading to production of progeny virus with a small plaque phenotype and significantly reduced virus titer ([@bib0390]).

3. Overview of the EAV life cycle {#sec0015}
=================================

EAV replicates primarily in equine macrophages and endothelial cells lining small blood vessels, but also in selected epithelia, mesothelium, and smooth muscle cells of the tunica media of smaller arteries, venules, and the myometrium ([@bib0090], [@bib0350], [@bib0645], [@bib0690], [@bib0730], [@bib0295], [@bib0925], [@bib0970]). Unlike other arteriviruses, EAV replicates *in vitro* in a variety of primary cell cultures, including equine pulmonary artery endothelial, horse kidney, rabbit kidney, and hamster kidney cells, and in a number of continuous cell lines such as baby hamster kidney (BHK-21), rabbit kidney-13 (RK-13), African green monkey kidney (VERO), rhesus monkey kidney (LLC-MK2), MARC-145, hamster lung (HmLu), SV-40 transformed equine ovary and canine hepatitis virus-transformed hamster tumor cells (HS and HT-7; [@bib0610], [@bib0665], [@bib0715], [@bib0740], [@bib0955]). Enveloped viruses typically have surface molecules that bind to cell surface receptors that mediate the process of cell attachment and membrane fusion with the host cell membrane. The viral envelope protein(s) involved in virus attachment and entry of EAV has not been fully characterized. [@bib0325] demonstrated that EAV expressing the ectodomain of GP5 of PRRSV IAF-Klop strain ([@bib0920]) did not change the cellular tropism of the virus. In a recent study, [@bib0715] unequivocally demonstrated that the ectodomains of GP5 and M of PRRSV are not the major determinants of cellular tropism, further supporting the conclusion that the minor envelope proteins are the critical proteins in mediating cellular tropism in arteriviruses ([@bib1180]).

While receptors for EAV have not yet been definitively identified, it is proposed that EAV is taken up *via* clathrin-dependent endocytosis and then delivered to acidic endosomal compartments ([@bib0875]). Following entry and release into the cytosol, the plus-stranded RNA genome is uncoated and translated into two replicase polyproteins (pp1a and pp1ab) from which at least 13 non-structural proteins (nsps) are released by autoproteolytic processing mediated by the viral proteases ([Fig. 3](#fig0015){ref-type="fig"}, [Fig. 4](#fig0020){ref-type="fig"}, [Fig. 5](#fig0025){ref-type="fig"} ; [@bib0385], [@bib1440]). The nsps assemble into a membrane-bound replication/transcription complex (RTC) ([@bib0650], [@bib0845]). Genome replication and sg mRNA transcription occur in the RTC and sg mRNAs are then translated into the viral structural proteins. The newly synthesized genome is encapsidated into the N protein to form the nucleocapsid, which becomes enveloped by budding through the endoplasmic reticulum--Golgi intermediate compartment (ERGIC) that contains membranes that include the viral envelope proteins. Newly formed virions mature in the Golgi complex during their movement through the exocytic pathway and are ultimately released from infected cells.Fig. 3Schematic overview of EAV life cycle. ER: endoplasmic reticulum; ERGIC: ER--Golgi intermediate compartment; NC: nucleocapsid.Fig. 4Schematic representation of the processing of the EAV replicase polyproteins (pp1a and pp1ab) and generation of individual nsps. The papain-like cysteine protease (PCPβ) and cysteine protease (CP) cleavage sites are indicated by black arrows. The M^pro^ cleavage sites are indicated by open arrowheads. The genes encoding structural proteins are depicted in gray. P and P\* are, PCP and CP, respectively; M^pro^, 3C-like main protease; Z, zinc-binding domain; C/H, cysteine/histidine-rich clusters; TM, predicted transmembrane domains; U, nidoviral uridylate-specific endoribonuclease (NendoU). Figure modified from *Nidoviruses* book chapter on the arterivirus replicase ([@bib1320]) with permission from ASM press.Fig. 5Proteolytic processing of EAV replicase polyprotein pp1a through the major and minor pathways. The papain-like cysteine protease (PCPβ) and cysteine protease (CP) cleavage sites are indicated by black arrows. The M^pro^ cleavage sites are indicated by open arrowheads. P and P\* are, PCP and CP, respectively; M^pro^, 3C-like main protease; C/H, cysteine/histidine-rich clusters; TM, predicted transmembrane domains.Figure modified from *Nidoviruses* book chapter ([@bib1320]) with permission from the *ASM Press*.

4. Genome organization, replication, and transcription {#sec0020}
======================================================

4.1. Genome organization {#sec0025}
------------------------

The EAV genome is a linear positive-sense single-stranded RNA molecule with a 5′-methylated nucleotide cap and a 3′-untranslated region followed by a poly (A) tail ([@bib1025], [@bib1035]). There are some 35 EAV full-length genome sequences available currently in GenBank ([Table 2](#tbl0010){ref-type="table"} ). The genome of individual virus strains varies between 12,704 and 12,731 bp, and includes a 5′ leader sequence (224 nucleotides \[nts\]) and at least ten open reading frames (ORFs, [Fig. 2](#fig0010){ref-type="fig"}; [@bib0050], [@bib0095], [@bib0310], [@bib0830], [@bib1295], [@bib1430]). The two most 5′-proximal ORFs (1a and 1b) occupy approximately three fourths of the genome ([Fig. 2](#fig0010){ref-type="fig"}). The replicase ORFs 1a and 1b are translated to produce polyproteins pp1a (1725 amino acids) and pp1ab (3176 amino acids; based on the published sequence of the EAV VBS strain \[ATCC VR-796\], GenBank accession number [DQ846750](ncbi-n:DQ846750){#intr0185}), with the latter being a C-terminally extended version of the former ([@bib0310]). ORF 1b translation depends on a −1 ribosomal frameshift (estimated efficiency 15--20%) just before termination of ORF 1a translation ([@bib0310]). The ORF 1a/1b overlap region contains signals that promote frameshifting: a so-called "slippery" sequence, the actual ribosomal frameshift site, and a downstream RNA pseudoknot structure. These two precursor proteins are extensively processed after translation into at least 13 nsps (nsp1--12, including nsp7 α/β; [Fig. 4](#fig0020){ref-type="fig"}, [Fig. 5](#fig0025){ref-type="fig"}, [Table 1](#tbl0005){ref-type="table"}) by three viral proteases (nsp1, nsp2, and nsp4) ([@bib0115], [@bib0300], [@bib1010], [@bib1035], [@bib1070], [@bib1075], [@bib1060], [@bib1200], [@bib1250], [@bib1255], [@bib1260], [@bib1270], [@bib1310], [@bib1300], [@bib1360], [@bib1440]). The greatest variation in the EAV replicase gene occurs in the portion of ORF1a encoding the nsp2 protein, with considerable variation at amino acids 388--488 ([@bib0050], [@bib0830], [@bib1415], [@bib1435], [@bib1425]). The remaining eight ORFs (2a, 2b, 3, 4, 5a, 5b, 6 and 7) are located in the 3′ quarter of the genome and encode eight structural proteins (seven envelope proteins and the nucleocapsid protein) of the virus (see below). Secondary structure analysis by chemical and enzymatic probing of 3′-end of the genome has identified two RNA domains that are essential for virus replication and most likely play a key role in viral RNA synthesis ([@bib0125]). The first domain, located directly upstream of the 39 untranslated region (UTR; nt 12,610--12,654 of the genome), is mainly single-stranded but contains one small stem--loop structure. The second domain is located within the 3′ UTR (nt 12,661--12,690) and folds into a prominent stem--loop structure with a large loop region. This second stem--loop structure may act as a recognition signal during the initiation of minus-strand RNA synthesis (see below).Table 2Full-length genome sequences of EAV strains available in the GenBank.Strain (size base pairs)SourceGenBank accession numberEAV Utr (12,704)[f](#tblfn0035){ref-type="table-fn"}Laboratory strain[NC_002532](ncbi-n:NC_002532){#intr0010}EAV030 (12,704)[c](#tblfn0020){ref-type="table-fn"}EAV infectious cDNA clone[Y07862](ncbi-n:Y07862){#intr0015}EAV Bucyrus (12,704)[d](#tblfn0025){ref-type="table-fn"}EAV virulent Bucyrus strain (VBS) horse passage 15 plural fluid (EAV ATCC VR-796)[DQ846750](ncbi-n:DQ846750){#intr0020}EAVrVBS (12,704)[d](#tblfn0025){ref-type="table-fn"}First EAV VBS infectious cDNA clone[DQ846751](ncbi-n:DQ846751){#intr0025}EAV HK25 (12,704)[c](#tblfn0020){ref-type="table-fn"}EAV VBS passage 25 in horse kidney[EU586273](ncbi-n:EU586273){#intr0030}EAV HK116 (12,704)[c](#tblfn0020){ref-type="table-fn"}EAV VBS passage 116 in horse kidney[EU586274](ncbi-n:EU586274){#intr0035}EAV ARVAC (12,704)[c](#tblfn0020){ref-type="table-fn"}MLV Vaccine[EU586275](ncbi-n:EU586275){#intr0040}pEAVrMLV (12,704)[g](#tblfn0040){ref-type="table-fn"}EAV MLV vaccine strain infectious cDNA clone[FJ798195](ncbi-n:FJ798195){#intr0045}Hela-EAVP35 (12,704)[c](#tblfn0020){ref-type="table-fn"}EAV VBS passage 35 in HeLa cells (laboratory strain)[EU252113](ncbi-n:EU252113){#intr0050}Hela-EAVP80 (12,704)[c](#tblfn0020){ref-type="table-fn"}EAV VBS passage 80 in HeLa cells (laboratory strain)[EU252114](ncbi-n:EU252114){#intr0055}EAV CW96 (12,708)[e](#tblfn0030){ref-type="table-fn"}Semen (EU-1)[AY349167](ncbi-n:AY349167){#intr0060}EAV CW01 (12,708)[e](#tblfn0030){ref-type="table-fn"}Semen (EU-1)[AY349168](ncbi-n:AY349168){#intr0065}EAV F63 (12,722)[a](#tblfn0010){ref-type="table-fn"}Semen (EU-2)[JN211320](ncbi-n:JN211320){#intr0070}EAV F61 (12,722)[a](#tblfn0010){ref-type="table-fn"}Semen (EU-2)[JN211318](ncbi-n:JN211318){#intr0075}EAV F27 (12,710)[a](#tblfn0010){ref-type="table-fn"}Semen (EU-2)[JN211316](ncbi-n:JN211316){#intr0080}EAV F62 (12,722)[a](#tblfn0010){ref-type="table-fn"}Semen (EU-2)[JN211319](ncbi-n:JN211319){#intr0085}EAV F60 (12,710)[a](#tblfn0010){ref-type="table-fn"}Semen (EU-2)[JN211317](ncbi-n:JN211317){#intr0090}EAV S4216 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903811](ncbi-n:GQ903811){#intr0095}EAV S3583 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903809](ncbi-n:GQ903809){#intr0100}EAV S3943 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903807](ncbi-n:GQ903807){#intr0105}EAV S3886 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903805](ncbi-n:GQ903805){#intr0110}EAV S3854 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903803](ncbi-n:GQ903803){#intr0115}EAV S3711 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903801](ncbi-n:GQ903801){#intr0120}EAV S3712 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903799](ncbi-n:GQ903799){#intr0125}EAV S3961 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903797](ncbi-n:GQ903797){#intr0130}EAV S3861 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903795](ncbi-n:GQ903795){#intr0135}EAV S3817 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903810](ncbi-n:GQ903810){#intr0140}EAV S4445 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903808](ncbi-n:GQ903808){#intr0145}EAV S4421 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903806](ncbi-n:GQ903806){#intr0150}EAV S4333 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903804](ncbi-n:GQ903804){#intr0155}EAV S4227 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903802](ncbi-n:GQ903802){#intr0160}EAV S4007 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903800](ncbi-n:GQ903800){#intr0165}EAV S4417 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903798](ncbi-n:GQ903798){#intr0170}EAV S3699 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903796](ncbi-n:GQ903796){#intr0175}EAV S3685 (12,731)[b](#tblfn0015){ref-type="table-fn"}Semen (EU-1)[GQ903794](ncbi-n:GQ903794){#intr0180}[^3][^4][^5][^6][^7][^8][^9]

4.2. Genome replication and transcription {#sec0030}
-----------------------------------------

The 5′ untranslated region (UTR) of the EAV genome, comprising approximately 225 nts functions as a protective element against degradation by exonucleases ([@bib0430]). According to the nidovirus transcription model proposed by [@bib0975], which is the most widely accepted model, sg mRNAs are produced by a discontinuous transcription mechanism controlled by the transcription regulatory sequence (TRS; "discontinuous extension of minus-strand RNA model" \[[Fig. 6](#fig0030){ref-type="fig"} \]). The TRS are short and conserved sequence elements (5′-UCAACU-3′ in EAV) that determine a base-pairing interaction between positive and nascent minus-strand RNA and are essential for leader-to-body joining ([@bib0900], [@bib0905], [@bib1335]). Similar to other nidoviruses, replication and transcription are processed through different minus-strand intermediates: a full-length minus-strand template is used for replication, while subgenome-sized minus strands produced during a process of discontinuous RNA synthesis are used to synthesize sg mRNAs ([Fig. 6](#fig0030){ref-type="fig"}; [@bib0895], [@bib0975], [@bib0980], [@bib1335]). The initiation of full-length minus-strand RNA (or anti-genome) synthesis, which is also used as template for new genome RNA replication, occurs after recognition of RNA signals near the 3′ end of the viral genome by the RNA-dependent RNA polymerase (RdRp) complex ([@bib1045]). Recognition signals located close to the 3′ end of the anti-genome are apparently used for production of new genomic RNA ([@bib0120], [@bib0125], [@bib1005]).Fig. 6Illustration of the transcription model in nidoviruses. The "discontinuous extension of minus-strand RNA model" proposes that an sg-length negative strand is produced that functions as a template for generation of sg mRNA ([@bib0975]). The anti-body TRS in minus-strand may serve as a "jump" signal of the nascent minus strand to leader TRS located at the 5′-end of the plus-strand full-length genome. After the anti-leader (-L) is added to the nascent minus strand, the sg-length minus strand functions as template for positive strand sg mRNA synthesis.Figure modified from [@bib0895] with permission from the *Journal of General Virology*.

The EAV sg mRNAs contain a common 5′ sequence of 211 nt called "leader", which is identical to the 5′ end of the viral genomic RNA ([@bib1035]). The leader TRS is located in a hairpin loop structure at the 3′ end of the leader ([@bib1265]) and the body TRSs are present upstream of every structural protein gene except ORFs 2b and 5a ([@bib0260], [@bib0305], [@bib0390], [@bib1055]). The EAV genome contains multiple UCAACU sequences that could be transcriptionally silent. Therefore, only a single TRS has been identified as an active site for each of the six sg mRNAs. Moreover, a number of 5′-UCAAC-3′ sequences were also identified in the replicase gene ([@bib0305]). However, multiple active TRSs per sg mRNA have been described and discontinuous RNA synthesis depends not only on base pairing between sense leader TRS and antisense body TRS, but also on the primary sequence of the body TRS ([@bib0885], [@bib0900], [@bib0905], [@bib0890], [@bib0895]). Introduction of site-specific mutations into the mRNA leader-body junctions of TRS strongly suggested that the discontinuous step occurs during minus-strand synthesis. While the leader TRS merely plays a targeting role for strand transfer, the body TRS fulfills multiple functions. Minus-strand RNA synthesis, initiated at the 3′-end of the viral genome, is attenuated at one of the body TRS regions ([@bib0895], [@bib0980]). Subsequently, the nascent minus-strand carrying the body TRS complement at its 3′ end is translocated to the 5′ end of the genomic template. In EAV, the genomic leader TRS serves as a base-pairing target for the 3′ end of the nascent minus-strand that is facilitated by its presence in the loop of an RNA hairpin. When minus-strand synthesis resumes, nascent strands are extended with the complement of the genomic leader sequence, yielding a nested set of subgenome-length minus-strand templates that are used for the subsequent synthesis of the various sg mRNAs. If attenuation does not occur, minus-strand RNA synthesis proceeds to yield a full-length complement of the genome, the intermediate being required for its replication. During the discontinuous transcription mechanism, the TRS at the 3′ end of the leader transcript base pairs with the complement of the body TRS in the negative-stranded template allowing extension of the complement of the genomic leader sequence in the nascent negative strand ([@bib0975]). The resulting sg negative-stranded RNA serves as template for the synthesis of the corresponding sg mRNA. With the exception of the last one, each sg mRNA, is structurally polycistronic, although they are functionally monocistronic and only the 5′-proximal ORF is translated from each sg mRNA. However, there are two exceptions, where sg mRNAs 2 and sg mRNA 5 are functionally bicistronic and each encode two structural proteins per sg mRNA ([@bib0390], [@bib1055]).

Formation of paired membranes and double-membrane vesicles (DMVs) at 3--6 h post-infection is a characteristic feature of arterivirus replication ([@bib0150], [@bib0930], [@bib0935], [@bib1125], [@bib1395]). The transmembrane nsps are incorporated into cellular organelles, particularly the ER, where early viral RNA synthesis occurs and results in increased expression of replicase proteins. Interaction of accumulated nsps with membranes results in membrane pairing and vesiculation ([@bib0915]). It is assumed that formation of DMVs that are derived from the endoplasmic reticulum (ER) is based on interactions between luminal domains of transmembrane proteins of either virus and/or cellular origin to bring opposite membranes together. The outer membranes of EAV-induced DMVs are interconnected with each other and with the ER, thus forming a reticulovesicular network (RVN) resembling that previously described in severe acute respiratory syndrome (SARS) coronavirus infected cells ([@bib0650]). Electron spectroscopic imaging of DMVs has revealed the presence of phosphorus in amounts equaling on average a few dozen copies of the EAV RNA genome. Furthermore, electron tomography has identified a network of nucleocapsid protein-containing protein tubules that appear to be intertwined with the RVN, which indicates there is a connection between EAV induced RVN and nucleocapsid assembly. Recently, it was also shown that autophagy marker protein microtubule-associated protein 1 light chain 3 (LC3) and ER degradation-enhancing alpha-mannosidase-like1 (EDEM1) are associated with DMV in EAV infected cells ([@bib0845]).

In nidovirus-infected cells, newly synthesized viral RNA and many replicase subunits are present in the perinuclear region together with a large number of DMVs ([@bib0915], [@bib1050], [@bib1285]). Immunoelectron microscopy revealed that viral nsps that are part of the replication/transcription complexes (RTC) and nascent viral RNA are associated with DMVs ([@bib0530], [@bib0655], [@bib0650], [@bib0915], [@bib1120], [@bib1285]). Therefore, DMVs are presumed to carry the enzyme complex responsible for virus replication and sg mRNA synthesis. Expression of EAV nsp2--3 is critical in inducing formation of DMVs ([@bib0915], [@bib1060]). Among the EAV replicase subunits, the nsp2, nsp3, and nsp5 encode a large number of hydrophobic regions that are presumed to have a structural function by inducing DMV formation ([@bib1060]) and anchoring the RTC to the membrane ([@bib1070], [@bib1290], [@bib1360]). More recently, isolated RTCs were shown to contain replicase subunits involved in DMV formation (nsp2 and nsp3) or viral replication (nsp9 and nsp10), and were co-sedimented with newly synthesized viral RNA in a heavy membrane fraction ([@bib1315]), which confirmed their association with DMVs and their essential role in RTC function.

4.3. Nonstructural proteins of EAV {#sec0035}
----------------------------------

The post-translational processing of the EAV replicase pp1a and pp1ab has been studied extensively ([@bib1005], [@bib1440] and references therein). In particular, pp1a and pp1ab undergo proteolytic processing at 11 cleavage sites by three virus-encoded proteinases (nsp1, nsp2, and nsp4) resulting in 13 nsps (1--12, including nsp7α and 7β; [Fig. 2](#fig0010){ref-type="fig"}, [Fig. 4](#fig0020){ref-type="fig"}, [Table 1](#tbl0005){ref-type="table"}; [@bib1260], [@bib1440]). Of these, the nsp9 to nsp12 subunits are encoded by ORF1b, although nsp9, the viral RNA-dependent RNA polymerase (RdRp), includes a small N-terminal ORF1a-encoded domain, which is identical to nsp8 and is encoded just upstream of the ribosomal frameshift site. The ORF1a encodes two papain-like cysteine protease domains ("accessory proteases" located in nsp1 and nsp2) and a chymotrypsin-like serine protease ("main protease") in nsp4. The ORF1a protein is cleaved at seven sites resulting in eight cleaved end products, nsp1 to nsp8, plus a number of processing intermediates ([@bib1070], [@bib1080], [@bib1360]). The ORF1b is processed into four major end products by nsp4 protease, including the RNA-dependent RNA polymerase (RdRp) and NTPase/RNA helicase domains essential for viral RNA replication and mRNA transcription ([@bib0310], [@bib0520]). Immunofluorescence studies have shown that the ORF1b-encoded replicase subunits are localized to the perinuclear region of EAV-infected cells suggesting that they may be associated with intracellular membranous compartments ([@bib1310]), most likely the ER. These observations were further confirmed by in-depth ultrastructural analysis of EAV-infected cells using electron tomography (see above; [@bib0650]). The mature nsps are involved in the formation of a membrane-anchored RTC that directs viral genome replication and synthesis of a nested set of sg mRNAs ([@bib0895], [@bib0980]). These three virus-encoded proteinases and their corresponding cleavage sites are well conserved in other arteriviruses.

**Nsp1** -- The 29-kDa nsp1 is the first viral protein expressed and is the most N-terminal replicase cleavage product produced. It contains an "accessory protease" that is not involved directly in proteolytic processing of the RdRp and helicase. Three domains have been identified in the nsp1 region: (1) A predicted zinc finger (ZF) domain; (2) A papain-like cysteine protease (PCP) α; and (3) PCPβ. The predicted ZF domain present near the N terminus of nsp1 contains four Cys and His residues ([@bib1320]). ZFs in many cellular transcription factors are involved in protein--nucleic acid and protein--protein interactions ([@bib0670]). The nsp1 is released from the replicase polyprotein by the autocatalytic activity of PCPβ, which is responsible for cleavage of nsp1/2, located in its C-terminal domain ([@bib1065], [@bib1070]). The cleavage and release of nsp1 from the replicase polyprotein is essential for viral RNA synthesis ([@bib1185]). In EAV, the PCPα is functionally inactive due to its loss of an active Cys site during virus evolution ([@bib0300]). However, PCPα may possess RNA-binding and/or protein-binding activities (along with PCPβ), serving as a platform for the ZF during transcription. Therefore, the structural integrity of nsp1 is essential since all three domains are required for trans-activation of sg RNA synthesis ([@bib1200]). It has been reported that nsp1 is essential for sg RNA transcription but dispensable for genome replication ([@bib1185]). The nsp1 not only plays a crucial role in processing of the replicase polyprotein and production of sg mRNA, but it is also important for virion biogenesis ([@bib1185]). Nsp1 is the only EAV replicase subunit that localizes both in the nucleus and cytoplasm where it associates with modified cytoplasmic membranes of the replication complex ([@bib0915], [@bib1195]). During the early stages of infection, nsp1 is primarily located in the nucleus while its cytoplasmic localization, especially in the perinuclear region, becomes evident later in infection ([@bib1195]). Nsp1 protein is also implicated in controlling the balance between genome replication and sg mRNA synthesis ([@bib0865]). Reverse and forward genetics studies have shown that nsp1 tightly controls the relative abundance of viral mRNA species in infected cells. In summary, nsp1 plays a major role in fine-tuning virus replication, sg mRNA synthesis, and virus production, and in coordinating the replicative cycle of arteriviruses.

**Nsp2** -- The 61-kDa nsp2 serves as a cofactor in the processing of the downstream part of the polyprotein directed by the nsp4 protease ([@bib1060]). The nsp2 contains two hydrophobic regions around aa 450 and 490 and a main hydrophobic region between aa 520 and 640, which are sufficiently large to span the lipid bilayer several times. However, the exact topology of this protein awaits further characterization ([@bib1060]). The N-terminal domain of nsp2 contains cysteine protease activity responsible for cleavage of the nsp2/3 site ([@bib1075]). Therefore, nsp2 is released from the polyprotein by internal cysteine autoprotease activity ([@bib1070]). In the major processing pathway, the mature nsp2 acts as cofactor for the processing of the nsp4/5 site by the nsp4 serine protease (SP; [Fig. 5](#fig0025){ref-type="fig"}). The nsp2 interacts strongly with nsp3 or nsp3-containing precursors (*e.g.* nsp3--8), a property that may be required for processing the nsp4/5 site by the nsp4 SP. When there is no interaction between nsp2 and nsp3--8, its internal site nsp4/5 cannot be cleaved and further processing of the replicase subunits occurs *via* the minor processing pathway ([Fig. 5](#fig0025){ref-type="fig"}).

Recently it has been shown that the nsp2 of arteriviruses has deubiquitinating enzyme (DUB) activity ([@bib1330]). The DUB enzymes remove ubiquitin from innate immunity signaling factors and provide a potential opportunity for viruses to evade host innate defense system. The DUBs of arteriviruses resemble the ovarian tumor domain-containing (OTU) family of DUBs. The arterivirus DUB domain resides in the N-terminal region of nsp2 and was previously shown to direct the proteolytic processing of the nsp2/3 site. In addition to its resemblance to OTU DUBs, the nsp2 protease belongs to the papain-like protease (PLP) family and therefore, it has been referred to as PLP2-DUB. Using both *in vitro* and cell-based assays, it has been shown that PLP2-DUB activity is conserved in all members of the arterivirus family and that DUB can inhibit RIG-I-mediated innate immune signaling when overexpressed in mouse embryonic fibroblast cells ([@bib1325]). These studies have also shown that the production of beta interferon (IFN-β) depends on the recognition of arterivirus RNA by the pattern-recognition receptor MDA5, and EAV PLP2-mutant viruses that lack DUB activity exhibit strikingly enhanced innate immune signaling in infected cells. Compared with wild type virus infection, IFN-β mRNA levels in equine cells infected with PLP2 mutants were increased by nearly a log 10 order of magnitude. The crystal structure of EAV PLP2 in complex with ubiquitin has been resolved and it has been shown that PLP2 binds ubiquitin using a zinc finger that is uniquely integrated into an exceptionally compact OTU-domain fold that represents a new subclass of zinc dependent OTU DUBs ([@bib1325]). The ubiquitin-binding surface is distant from the catalytic site, which explains how mutation(s) on this surface can reduce DUB activity without affecting polyprotein cleavage. These new findings not only established PLP2 DUB activity as a critical factor in innate immune evasion of EAV (and other arteriviruses), but the selective inactivation of DUB activity also offers an innovative strategy for developing improved MLV vaccines against arteriviruses encoding similar dual-specificity proteases.

**Nsp3** -- The 22-kDa nsp3 is highly hydrophobic and is presumed to be a tetra-spanning transmembrane molecule ([@bib0945]). It contains four conserved cysteine residues in the predicted first luminal domain (aa 853--902) that are likely to be involved in membrane pairing and DMV formation ([@bib0945]). Due to the multiple spanning nature of the protein, nsp3 is likely to play a key role in the interaction between the RTC and host cell membranes. Site-directed mutagenesis studies have shown that mutation of nsp3 impairs the interaction of the protein with the ER, disrupts the formation of DMVs, affects replicase polyprotein processing, and inhibits viral RNA synthesis ([@bib0945], [@bib1060]). It is possible that the N-terminal domain (aa 833--993) of nsp3 could function as a signal sequence for membrane insertion of nsp2/3 polyprotein before its cleavage by nsp2 ([@bib0945]). However, the mechanism of interaction between nsp3 and the membranes or with other replicase subunits involved in DMV formation remains poorly understood.

**Nsp4** -- The 21-kDa nsp4 has chymotrypsin-like SP activity at the N-terminal domain ([@bib0115]). The nsp4 includes a unique C-terminal domain (CTD) connected to the catalytic two-barrel structure by aa residues 155 and 156 that are poorly conserved among arteriviruses ([@bib1250], [@bib1255]). The three-dimensional structure of EAV nsp4 has been determined to 2.0 Å resolution, showing that nsp4 adopts the smallest known chymotrypsin-like fold with a canonical catalytic triad of Ser-120, His-39, and Asp-65, and a novel alpha/beta C-terminal extension domain that may play a role in mediating protein--protein interactions ([@bib0115]). As the protease name indicates, the main catalytic residue of this C-like protease in arteriviruses is Ser. Nsp4 is the "main protease" that controls the production of the viral RNA-dependent RNA polymerase and RNA helicase ([@bib0525], [@bib1440]). It is responsible for processing the polypeptides (nsp3--8 and nsp3--12) that remain after nsp1 and nsp2 have been autocatalytically released from pp1a and pp1ab ([@bib0115], [@bib1065], [@bib1070], [@bib1075], [@bib1080], [@bib1300], [@bib1360]). The nsp4 SP cleaves at five sites in the ORF1a protein ([@bib1080]) and three sites in the ORF1b protein ([@bib1360]). The nsp4 SP processes the C-terminal half of the ORF1a (nsp3--8) protein *via* two alternative pathways ([Fig. 5](#fig0025){ref-type="fig"}). In the major processing pathway, nsp2 associates with nsp3--8 (96 kDa) as a cofactor that triggers nsp4 SP to cleave the majority of nsp3--8 precursors at the nsp4/5 site resulting in nsp3--4 (50 kDa) and nsp5--8 (44 kDa) intermediates. Subsequently, the nsp5--8 is cleaved at the nsp7/8 site while the nsp5/6 and nsp6/7 are inaccessible to the protease ([@bib1360]). In the minor processing pathway, the nsp4/5 site remains intact while the nsp5/6 and nsp6/7 sites are cleaved ([Fig. 5](#fig0025){ref-type="fig"}; [@bib1360]). Furthermore, it was also shown using reverse genetic analysis that all nsp4-mediated cleavages in EAV pp1a are critical for viral RNA synthesis ([@bib0115]). In addition, these studies identified a novel cleavage site for the nsp4 protease, which is located within the nsp7 subunit and appears to be conserved among arteriviruses ([@bib1260]).

**Nsp5, nsp6, nsp7α/β, and nsp8** -- The processing intermediate nsp5/6/7/8 is a result of cleavage of the nsp4/5 junction upon association of nsp2 as a cofactor with nsp3--8. In the major pathway, nsp3/4 and nsp7/8 junctions are cleaved, but not the nsp5/6 and nsp6/7 ([Fig. 5](#fig0025){ref-type="fig"}); therefore, cleaved nsp6 and nsp7 are not generated. In the minor pathway, nsp4/5 is not cleaved; instead, nsp4 cleaves the nsp3/4, nsp5/6, nsp6/7, and nsp7/8 junctions of the nsp3--8 intermediate producing cleaved nsp6 and nsp7 ([@bib1360]). Fully processed nsp5, nsp6, nsp7, and nsp8 are approximately 41, 3, 25, and 5.5 kDa, respectively ([@bib1070]).

The nsp5 contains a significant portion of the highly hydrophobic domain suggesting a role in the membrane association of the EAV replication complex ([@bib1070], [@bib1290]). Moreover, the presence of hydrophobic nsp5 in the N-terminus of processing intermediates, like nsp5--8, nsp5--7 and even larger intermediates such as nsp5--12, supports its probable association with the intracellular membrane ([@bib1290]). There is little published information regarding the nsp6 and nsp8 proteins ([@bib1070]). An internal cleavage site (nsp7α/β) is present in mature nsp7 that is cleaved by nsp4 protease to produce nsp7α (123 aa; ∼13.5 kDa) and nsp7β fragments, respectively, corresponding to the N- and C-terminal regions of nsp7 ([@bib1260]). Most recently, the structure of nsp7α, the most conserved region of nsp7, has been determined by nuclear magnetic resonance (NMR) spectroscopy ([@bib0750]). The nsp7α contains four hydrophobic regions needed for correct folding of the proteins and has a unique conformation consisting of three α-helices packed against a mixed β-sheet. Although this study did not provide a definite conclusion regarding the function of nsp7, it confirmed that nsp7α is critical for arterivirus RNA synthesis.

**Nsp9** -- The 80-kDa EAV nsp9 (aa 1678--2370 of pp1ab) contains the RdRp domain that functions as the catalytic subunit of the viral RTC and directs viral RNA synthesis in conjunction with other viral proteins and host cellular proteins. The EAV nsp9/RdRp initiates RNA synthesis by a *de novo* mechanism involving homopolymeric templates in a template-specific manner. Increased intracellular concentration of Zn^2+^ can block the initial step of viral RNA replication carried out by nsp9/RdRp ([@bib1170]).

**Nsp10** -- The 51-kDa EAV nsp10 contains a predicted zinc-binding domain (ZBD) in its N-terminus and the nucleoside triphosphate-binding/helicase (Hel) motif in its C-terminal domain ([@bib0310], [@bib0520], [@bib1305]). The nsp10 is the most conserved replicase subunit of the viral RNA synthesis machinery ([@bib0515], [@bib0500], [@bib0510]). The nsp10 has ATPase and nucleic acid duplex-unwinding activities that require the presence of 5′ single-stranded regions indicating 5′--3′ polarity of the reaction ([@bib1000]). The ZBD region, especially the 13 conserved Cys and His residues that are most likely to be associated with zinc binding, is critical for ATPase and duplex-unwinding activities of the C-proximal helicase domain ([@bib0310], [@bib0520], [@bib0995], [@bib1305]). Reverse genetic studies have shown that mutation of conserved Cys/His residues in ZBD disrupted interactions between the ZF and enzymatic domains, thus completely blocking viral RNA synthesis and virion biogenesis ([@bib0995], [@bib1305]). Taken together, the nsp10-associated ZF domain has multiple functions specifically involved in viral RNA replication, sg mRNA transcription and virion biogenesis ([@bib1305]).

**Nsp11** -- The 26-kDa nsp11 is a multifunctional protein with a crucial role in viral RNA synthesis. The nsp11 contains a highly conserved endoribonuclease (NendoU; *[n]{.ul}idoviral*-*endonuclease* specific for *U*) domain that is not present in other RNA viruses and is therefore considered a unique genetic marker of the order *Nidovirales* ([@bib0615], [@bib0940]). The NendoU possesses pyrimidine-specific (uridylates in particular) endoribonuclease activity independent of divalent cations (*e.g.* Mn^2+^) *in vitro* ([@bib0870]). Studies using reverse genetics have shown the importance of NendoU activity for viral RNA synthesis ([@bib0870], [@bib0940]). However, identification of substrate and molecular characterization of NendoU remain unclear.

**Nsp12** -- There is no published information regarding either the structure or role of the 12-kDa nsp12 of arteriviruses.

4.4. Structural proteins of EAV {#sec0040}
-------------------------------

### 4.4.1. Major envelope proteins {#sec0045}

**GP5** -- The 30- to 42-kDa GP5 protein is an abundant virion protein encoded by ORF5. GP5 typically contains either one or two potential N-glycosylation sites (Asn-56 and Asn-81), and the majority of laboratory adapted EAV strains contain only the N-linked sugar moiety at position Asn-56 ([Fig. 7](#fig0035){ref-type="fig"} ; [@bib0080], [@bib0445], [@bib1100]). A third potential N-glycosylation site at aa 73 (Asn-73) was identified in five EAV isolates from clinical specimens obtained during the extensive 2006--2007 outbreak of EVA in the US ([@bib1430]). The GP5 protein is a type IV integral membrane protein with triple-membrane spanning domains from aa 116 to 181 ([Fig. 7](#fig0035){ref-type="fig"}) ([@bib0265]). The ectodomain of GP5 includes 95 aa and contains an N-terminal signal sequence (aa 1--18) that is cleaved ([@bib1030]). The smear appearance of the GP5 protein after analysis by denaturing SDS-PAGE is due to the addition of poly-N-acetyllactosamine during its transport through the secretory pathway ([@bib0265], [@bib0275]). However, the function of poly-N-acetyllactosamine modification of the GP5 protein is unclear.Fig. 7Predicted structure of GP5 and M heterodimer. The predicted N-glycosylation sites (Asn-56 and Asn-81) are depicted with an orange circle. The green circle represents the N-glycosylation site (Asn-73) found in isolates of an extensive recent EVA outbreak in North America. The GP5 and M proteins are covalently linked by a disulfide bond (S---S) formed between Cys-34 in the GP5 protein and Cys-8 in the M protein. The major neutralization determinants of EAV that are located in the N-terminal ectodomain of the GP5 major envelope glycoprotein of EAV are depicted. The signal sequence (aa 1--18), four major neutralization sites (A, B, C and D) and putative glycosylation sites (aa positions 56, 73 and 81) are identified.

Equine EAV-specific polyclonal antisera and EAV-neutralizing monoclonal antibodies bind to the N-terminal hydrophilic ectodomain (aa 19--115) of GP5 ([@bib0080], [@bib0195], [@bib0315], [@bib0445], [@bib0880]). Four distinct neutralization determinants of the virus have been identified in GP5: aa 49 (site A), 61 (site B), 67--90 (site C), and 98--106 (site D; [Fig. 7](#fig0035){ref-type="fig"}; [@bib0085], [@bib0075], [@bib0080], [@bib0195], [@bib0315], [@bib0445], [@bib1435]). Except for site A located in the C~1~ region, these sites are located in the V~1~ variable region (aa 61--121) within the second half of the N-terminal ectodomain. Site D expresses several overlapping linear epitopes in the protein that may possibly interact with the three other sites to form conformational epitopes ([@bib0075], [@bib0080], [@bib0030], [@bib0445]).

**Membrane (M) protein** -- The 16-kDa M protein is encoded by ORF6. The M protein is the most highly conserved envelope protein of arteriviruses ([@bib0265]). The M protein has three internal membrane-spanning segments and a short amino terminus exposed at the virion surface (aa 10--18), and its carboxy-terminus (approximately aa 72) is buried within the virus' interior ([Fig. 7](#fig0035){ref-type="fig"}; [@bib0265], [@bib1035]). It lacks N-glycosylation sites and contains five methionine residues and one cysteine. The M protein forms a disulfide-linked heterodimer with the GP5 protein in the virus particle ([@bib0275]). The M protein also forms covalently linked homodimers, but only the GP5/M heterodimers are incorporated into virus particles. It is possibly involved in virus budding.

### 4.4.2. GP5/M heterodimeric complex {#sec0050}

The GP5 and M proteins form a disulfide-linked heterodimer in the virus particle and occur in equimolar amounts in the virion ([Fig. 7](#fig0035){ref-type="fig"}; [@bib0275]). These proteins associate with each other with different kinetics and efficiencies in infected cells. Newly synthesized GP5 proteins rapidly interact with M protein, while newly produced M proteins are incorporated slowly into the heterodimer. Presence of a high concentration of M protein in the ER is a prerequisite for efficient recruitment of GP5 protein into the GP5/M heterodimeric complex ([@bib0275]). The interaction between the two major envelope proteins is determined by the formation of the disulfide bridge between the cysteine residue at position 8 (Cys-8) of M and Cys-34 of GP5 since abolition of either cysteine residue completely inhibited heterodimerization of the two proteins ([@bib1030]). Heterodimerization of the two major envelope proteins is essential for EAV infectivity. Studies using chimeric viruses have shown that replacement of the EAV GP5 ectodomain with that of different arterivirus species did not alter the cell tropism of EAV, indicating that GP5 is not involved in receptor binding ([@bib0325]).

The GP5/M heterodimeric complex is essential for EAV assembly where the interaction between nucleocapsid and viral envelope is most likely mediated by the disulfide-bonded GP5/M heterodimers since the minor envelope proteins are not required for generation of virus particles. Covalent association of the GP5 and M proteins is indispensable for the production of infectious arteriviruses ([@bib1030], [@bib1345]). It has been clearly demonstrated that heterodimerization of the GP5 and M proteins is critical for the authentic post-translational modification (glycosylation) and conformational maturation of the neutralization determinants in GP5 ([@bib0060], [@bib0030]). The M protein may act as an essential scaffold on which the GP5 protein folds to form the epitopes that induce neutralizing antibodies in virus-infected animals. Nonetheless, peptides derived from portions of the GP5 ectodomain can induce EAV-neutralizing antibodies in horses ([@bib0175], [@bib0195]).

### 4.4.3. Minor envelope proteins {#sec0055}

**E protein** -- The EAV E protein is a small 8 kDa protein encoded by ORF2a ([@bib1055]). ORF2a and ORF2b are both expressed from a bicistronic mRNA2. The E protein lacks N-linked oligosaccharide side chains and its single cysteine residue does not form intermolecular disulfide bonds. E protein is stable, highly hydrophobic, and predicted to be an integral membrane protein with an uncleaved signal-anchor sequence in the central part of the molecule ([Fig. 8](#fig0040){ref-type="fig"} ). E protein could be either a type III integral membrane protein or it may span the lipid bilayer twice with both termini located in the cytoplasmic face of the membrane ([@bib1055]). It contains a conserved site for myristoylation in the N-terminal domain followed by a phosphorylation site for casein kinase II ([@bib1175]). The E protein occurs in intermediate amounts in infected cells, as compared to the major structural proteins ([@bib1055]). It has been suggested that the E protein is noncovalently associated with the GP2, GP3 and GP4 trimeric complex. In the absence of the minor envelope protein complex, the amount of E protein in viral particles is diminished by 60--80%. Similarly, the absence of E protein completely blocks the incorporation of the minor envelope proteins (GP2, GP3, and GP4) into viral particles ([@bib1390]). These findings suggest that the E protein along with GP2 is essential for the production of infectious progeny virus but dispensable for virus assembly and release ([@bib1055]). The E protein may have an intermediate receptor binding and/or virus entry function with the GP2/GP3/GP4 complex ([@bib0250]). It has been also shown that the porcine arterivirus (PRRSV) E protein possesses ion channel protein-like properties and is essential for virus infection but dispensable for virion assembly ([@bib0695], [@bib1400]).Fig. 8Predicted membrane topology of the minor envelope proteins: E, GP2, GP3, GP4, and ORF5a protein. Two alternative predictions of E protein and GP3 membrane topology are shown. Putative N-glycosylation sites are indicated in yellow circles with corresponding amino acid positions.

**GP2** -- The GP2 protein is a 25 kDa minor envelope protein encoded by ORF2b ([Fig. 8](#fig0040){ref-type="fig"}). GP2 is a type I membrane glycoprotein with a single N-glycosylation site at position 155 (Asn-155) ([@bib0280]). It has three amino-terminal (extracellular) cysteine residues likely to be important for dimerization and protein function, and one in its transmembrane anchor domain ([@bib0280]). The Cys-102 is responsible for the cystine bridge with the GP4 protein while Cys-48 and Cys-137 form an intramolecular disulfide bond ([@bib1375]). The GP2 protein occurs in several distinct conformations, including as four monomers as a result of different disulfide-bonded structures and as a disulfide-linked dimer ([@bib0280]). However, only the dimeric form of GP2, which is further associated with GP3 and GP4 proteins as a heterotrimeric complex, is assembled into viral particles whereas the GP2 monomers are retained in the endoplasmic reticulum of infected cells ([@bib0280]). GP2 is abundant in EAV-infected cells, but is expressed in low amounts in viral particles. The GP2 protein is not essential for viral RNA replication and transcription ([@bib0840], [@bib1055]). Sequence comparison analysis indicates that the GP2 protein is highly conserved between EAV isolates ([@bib0550]).

**GP3** -- The GP3 is encoded by ORF3 and is a membrane-associated protein of 36--42 kDa with six potential N-glycosylation sites, Asn-28, Asn-29, Asn-49, Asn-96, Asn-106, and Asn-118 ([@bib0545], [@bib1380]). The membrane topology of GP3 proteins has still not been clearly demonstrated. The protein could be either a class II protein, anchored into the lipid bilayer by its uncleaved amino-terminal signal sequence, or a class IV protein, possibly embedded by both sides of the hydrophobic terminal domains ([Fig. 8](#fig0040){ref-type="fig"}; [@bib0545], [@bib1380]). The GP3 protein has two putative N-myristoylation sites and three casein kinase II phosphorylation motifs but it is unclear whether they are active sites. Little is known about the function of this protein; however, inactivation of ORF3 expression inhibited the production of infectious virus particles indicating that GP3 protein has an essential role in the viral replication cycle.

**GP4** -- The GP4 protein, encoded by ORF4, is a typical class I integral membrane glycoprotein with amino-terminal signal sequence and its predicted carboxy-terminal hydrophobic membrane anchor ([Fig. 8](#fig0040){ref-type="fig"}; [@bib1380]). Three of the four predicted N-glycosylation sites (Asn-33, Asn-55, Asn-65, and Asn-90) are functional and produce a fully glycosylated protein with a molecular mass of 28 kDa ([@bib1380]). However, [@bib1380] reported that N-glycosylation of the GP4 protein is an inefficient process so that only some of the protein molecules acquire N-linked glycans in EAV-infected cells. Moreover, only the fully glycosylated form of GP4 is present in virus particles, which indicates that only a small fraction of the ORF4 products produced in EAV-infected cells are incorporated into virus particles ([@bib1380]). The function of GP4, like that of the GP3 protein, is not well characterized, but both are essential in the viral replication cycle.

**ORF5a protein** -- A detailed computational analysis revealed an additional ORF (ORF5a) that overlaps the 5′ end of ORF5, and is conserved in all arterivirus species ([@bib0390], [@bib0625]). The ORF5a protein is 59 aa and is likely to be expressed from the same subgenomic mRNA (sg mRNA5) as the GP5 protein, possibly involving leaky ribosomal scanning. The ORF5a protein is predicted to be a type III membrane protein with a short (5--12 aa) amino terminal domain into the lumen, a central signal-transmembrane sequence and a carboxy-terminal domain into the cytosol ([Fig. 8](#fig0040){ref-type="fig"}; [@bib0625]). The function of this protein is yet to be characterized, but reverse genetic studies suggest that this novel protein may be the eighth structural protein of arteriviruses and important for arterivirus infection.

### 4.4.4. GP2/GP3/GP4 heterotrimeric complex {#sec0060}

The GP2, GP3, and GP4 proteins are incorporated into virions as a covalently associated heterotrimeric complex and lack of any one of the components blocks the successful incorporation of the other minor envelope proteins ([@bib1390]). After the release of virus particles from infected cells, GP3 becomes disulfide-linked to the GP2/GP4 heterodimers which results in a 66-kDa complex consisting of covalently bound GP2, GP3, and GP4 ([@bib1385]). Due to this post-assembly modification, both GP2/GP4 heterodimers and GP2/GP3/GP4 heterotrimers are detected in EAV particles ([@bib1385]). Cystine bridges play essential roles in the formation and stabilization of the trimeric complex. The cysteine residues at positions 48 and 137 (Cys-48 and Cys-137, respectively) of GP2 are linked by an intra-chain disulfide bond while the cysteine residue at position 102 (Cys-102) of GP2 forms an intermolecular cystine bridge with one of the cysteines of the GP4 protein ([@bib1375]). The covalent association of GP3 with the GP2/GP4 heterodimer likely occurs through the GP4 protein; however, the precise cysteine residue forming the intermolecular disulfide bond between GP4 and GP3 has not yet been determined ([Fig. 9](#fig0045){ref-type="fig"} ). Similarly, the cysteine residue of GP4 that interacts with Cys-102 of GP2 has not been identified. It has been shown that folding and oligomerization of GP2, GP3, and GP4 expressed in *E. coli* are independent processes ([@bib0635]). However, it remains to be shown whether this is true in virus-infected cells. The GP2/GP3/GP4/E heterotrimeric complex is most likely involved in the virus entry process into the cell based on the observation that it is not required for EAV virus particle formation, but is essential for production of infectious progeny virus.Fig. 9Two predicted models for the disulfide-bonded structure of the covalently linked GP2---GP3---GP4 heterotrimer. These alternative models differ in membrane topology of GP3, which is currently uncertain. The GP3 protein may be either a class II membrane protein (A) or a class IV membrane protein (B). The intermolecular cystine bridges are depicted arbitrarily with disulfide bonds (S---S) since the Cys positions have not yet been determined. N-glycosylation sites are indicated in orange circles with corresponding amino acid positions.Modified from [@bib1385] with permission.

### 4.4.5. Nucleocapsid (N) protein {#sec0065}

The 14-kDa N protein, encoded by ORF7, is the most abundant viral protein in EAV-infected cells. The N protein is synthesized in the cytoplasm of EAV-infected cells and possibly binds to envelope protein domains exposed to the cytoplasm during the budding process. Most of the N protein localizes in the cytoplasm of infected cells, whereas a small amount resides in the nucleus where it apparently accumulates in nucleoli. This suggests a possible post-translational modification of some molecules of N protein, such as phosphorylation. The N-terminal domain (aa 1--47) of the N protein, the least conserved region, is thought to interact with the viral genomic RNA during nucleocapsid assembly ([@bib1195]). The C-terminal (aa 49--110) of the N protein forms a dimer consisting of a β-sheet that is capped and flanked by α-helices. In the crystal structure, the N protein forms a dimer--dimer (*i.e.* a tetramer), organized *via* a quasi-twofold axis ([@bib0320]). The N protein comprises more than 30% of the protein molecules in EAV particles.

5. Host--virus interactions {#sec0070}
===========================

5.1. Pathogenesis {#sec0075}
-----------------

Although it is abundantly clear that many of the clinical manifestations of EVA result from vascular injury, the pathogenesis of EVA has not yet been comprehensively defined. Studies with the highly virulent, horse-adapted Bucyrus strain of EAV confirm that death in horses inoculated with this virus is a consequence of severe vascular damage potentially leading to disseminated intravascular coagulation ([@bib0290], [@bib0295], [@bib0705], [@bib0730]). Similarly, endothelial infection is characteristic of EVA in horses naturally infected with the virus ([@bib0290], [@bib0295]). The characteristic vascular lesions of EVA have been compared to those of Aleutian disease of mink and other immune-mediated vascular diseases ([@bib0145], [@bib0570]), however, the lesions of EVA do not appear to be the result of immune-mediated injury because they develop at only 4--5 days after experimental inoculation, which is not consistent with a typical immune-mediated process. Furthermore, arteries larger than 1 mm may be affected, and neither immunoglobulin G (IgG) nor complement (C3) are present in the lesions, as would be expected if immune complexes were responsible. Therefore, vascular injury in EVA likely results from direct virus-mediated injury to the lining (endothelium) of affected vessels perhaps exacerbated by the activity of virus-induced, host-derived procoagulant and proinflammatory mediators. In muscular arteries, EAV infects and replicates in endothelial cells (ECs) and causes extensive damage to the endothelium and the subjacent internal elastic lamina, then gains access to the media of the wall of affected vessels. Increased vascular permeability and leukocyte infiltration resulting from generation of chemotactic factors lead to hemorrhage and edema around these vessels ([@bib0230], [@bib0375]).

EAV infects alveolar macrophages (AMΦ) after respiratory infection of horses, but recent *in vitro* studies using cultured equine AMΦ confirmed that although these cells were susceptible to infection, they were refractory to productive replication of EAV ([@bib0850]). In contrast, productive replication occurred following EAV infection of cultured blood-derived equine macrophages (BMΦ; [@bib0850]). EAV infection of both equine AMΦ and BMΦ resulted in increased transcription of genes encoding proinflammatory mediators, including IL-1β, IL-6, IL-8, and TNF-α, with the release of substantial quantities of TNF-α into the culture medium ([@bib0850]). Furthermore, virulent and avirulent strains of EAV induced different quantities of TNF-α and other proinflammatory cytokines (IL-1b, IL-6, IL-8), and the magnitude of the cytokine response of equine AMΦ and BMΦ to EAV infection reflected the virulence of the infecting virus strain ([@bib0850]). In addition, expression of leukocyte adhesion molecules is upregulated following EAV infection. Not only may these factors be important in inciting inflammation to limit initial virus replication, they may also contribute to the vascular and tissue injury that characterizes EVA. In summary, these *in vitro* studies clearly showed that cytokine mediators are produced by EAV infected equine cells and, presumably, these mediators can play an important role in determining the nature and severity of the outcome of infection. However, full characterization of the innate and adaptive immune responses of horses to EAV infection have not yet been done and, in particular, the likely central role of dendritic cell infection should be addressed. Similarly, although EAV causes lytic infection in susceptible cells, the mechanism(s) of cell death remains poorly characterized. EAV infection induces apoptosis by activation of caspase 8 and caspase 9 after infection of Vero cells ([@bib0025], [@bib1095]), and apoptosis in EAV infected BHK-21 cells is mediated through the intrinsic signaling pathway ([@bib0220]). Taken together, these data provide evidence that EAV is able to induce apoptotic cell death *in vitro*. However, in-depth mechanism(s) of apoptosis or the significance of apoptosis in pathogenesis of EVA during natural infection has not been investigated.

Abortion after EAV infection of pregnant mares likely is the result of a lethal fetal infection, rather than myometritis or placental damage that impairs progesterone synthesis, leading to fetal expulsion ([@bib0735]). The tissues of aborted fetuses contain higher titers of virus than those of the dams from which they abort, indicating that substantial virus replication can occur in the fetus itself. The stress that results from fetal infection would be expected to activate the fetal hypothalamic-pituitary axis, thus inducing abortion.

5.2. Use of infectious cDNA clones of EAV and reverse genetics {#sec0080}
--------------------------------------------------------------

The naked genome of a positive-strand RNA virus is infectious: it serves as an mRNA for translation of viral replicase, thus, infection can be initiated by a simple transfection of the genome into the host cell. Construction of full-length cDNA clones of plus-stranded RNA viruses have facilitated studies in which site-specific nucleotide changes (site-directed mutagenesis) are introduced into the viral genome to study the mechanisms of virus replication and gene expression at the molecular level. Similarly, entire portions of the genome of different virus strains, or related viruses, can be exchanged to produce recombinant chimeric viruses. Infectious RNA transcripts are produced *in vitro* from linearized full-length infectious cDNA clones transfected into mammalian cells. Such infectious cDNA clones of RNA viruses are used not only as basic research tools, but also to develop rational vaccines against viral pathogens.

The original infectious cDNA clones of EAV were derived from a highly cell culture adapted strain of the virus ([Table 2](#tbl0010){ref-type="table"}; [@bib0270], [@bib0450], [@bib1295]) and the recombinant progeny virus derived from the first EAV infectious cDNA clone (GenBank accession number: [Y07862](ncbi-n:Y07862){#intr0190}; [@bib1295]), pEAV030 is attenuated in horses ([@bib0100]). Snijder and colleagues did pioneering work to characterize the molecular biology of EAV and other nidoviruses using the pEAV030 infectious cDNA clone ([@bib1005], [@bib1010], [@bib1040], [@bib1050], [@bib1015]). Specifically, they used this infectious cDNA clone to characterize the mechanism of EAV replication along with processing of viral non-structural proteins ([@bib0300], [@bib1015], [@bib1020], [@bib1250], [@bib1255], [@bib1300]), transcription and subgenomic mRNA synthesis ([@bib1200], [@bib1185], [@bib1190], [@bib1265], [@bib1305], [@bib1335], [@bib1340]), and the viral replication complex ([@bib1060], [@bib1050]). This clone also apparently contributed to the publications of other groups ([@bib0270], [@bib0450]). [@bib0030], [@bib0050] employed site-directed mutagenesis of this same infectious cDNA clone to generate a panel of chimeric and mutant viruses to characterize the neutralization determinants of EAV ([@bib0030]). The third infectious cDNA clone of EAV was derived from the horse-adapted, experimentally derived, highly virulent Bucyrus strain (VBS) of the virus ([@bib0095]). The recombinant virus generated from this infectious cDNA clone (prVBS) causes severe disease and high lethality in experimentally infected horses ([@bib0095]). Recently, a full-length cDNA clone of the MLV vaccine strain (prMLV) that was originally derived by extended cell culture passage of the Bucyrus strain of EAV (VBS) has also been constructed ([@bib1410]). These two related infectious cDNA clones have been used to generate a panel of chimeric viruses by swapping genes encoding minor and major envelope viral proteins from virulent and avirulent viruses to characterize the tropism of EAV to equine peripheral blood mononuclear cells ([@bib0495]).

Reverse genetic manipulation of infectious cDNA clones of EAV has greatly increased the understanding of the replication of the virus and its molecular biology and pathogenesis, however, manipulation of the genome of arteriviruses is complicated due to the compact and overlapping gene arrangement. [@bib0270] investigated the importance of the overlapping gene organization in the virus' life-cycle by constructing a series of mutant full-length cDNA clones in which EAV ORFs 4/5 or ORFs 5/6 or ORFs 4/5/6 were separated ([@bib0270]). RNA transcribed from each of these plasmids was infectious, indicating that the overlapping gene arrangement is not essential for viability of the virus. The fact that small changes in the spacing between ORFs 4/5 and ORFs 5/6 in the mutant viruses had only a limited effect on virus yields allowed the generation of recombinant chimeric viruses between virulent and attenuated strains of EAV. Thus, genes encoding structural and nonstructural proteins can readily be interchanged between strains of EAV of differing virulence to horses, and these chimeric viruses have then been used to study virulence determinants, mechanisms of pathogenesis and persistent infection ([@bib0495], [@bib1415], [@bib1425]). A similar approach has been used to construct a panel of EAV/PRRSV chimeric viruses by swapping GP5 and M proteins (ectodomains and full-length) of PRRSV into pVBS cDNA clone backbone ([@bib0715]).

EAV cDNA clones have also been used as a vector for heterologous gene expression ([@bib0270]), such as enhanced green fluorescence protein (eGFP; [@bib0270], [@bib1270]). The infectious recombinant EAV expressing GFP (EAV-GFP2) from its replicase had similar growth characteristics to those of the wild-type virus. The recombinant virus EAV-GFP2 is a convenient tool for basic and applied research studies. The same approach, namely insertion of a foreign gene in the arterivirus replicase gene for intracellular expression, could also be used for vaccine development.

5.3. Viral factors {#sec0085}
------------------

Using the reverse genetics approach, the virulence determinants of EAV have been mapped to genes encoding both nonstructural (nsp1, nsp2, nsp7, and nsp10) and structural proteins (GP2, GP4, GP5, and M; [@bib1415]). However, it appears that the most important virulence determinants of EAV are located in the structural protein genes of the virus. The interaction among the GP2, GP3, GP4, GP5, and M envelope proteins plays a major role in determining the tropism of EAV for CD14^+^ monocytes, whereas tropism for CD3^+^ T lymphocytes is determined by the GP2, GP4, GP5, and M envelope proteins but not the GP3 protein ([@bib0495]). Using an *in vitro* cell culture model of persistent EAV infection, it has been shown that combined amino acid substitutions in E, GP2, GP3, and GP4 proteins or a single amino acid substitution in the GP5 protein could facilitate persistent EAV infection in HeLa cells ([@bib1425]). However, the viral protein(s) involved in establishment of persistent infection in the stallion\'s reproductive tract are yet to be definitively identified. In summary, the virulence determinants of EAV appear to be complex and to involve multiple genes encoding both envelope and nonstructural proteins (multigenic).

5.4. Application of equine genomics {#sec0090}
-----------------------------------

Viruses constantly adapt to and modulate the host environment to their advantage during replication and propagation. Therefore, virus interaction with host target cells is complex and it is possible that almost every step of the virus infection cycle may rely on the recruitment and co-opting of cellular proteins and basic machineries by viral proteins. Moreover, as a virus that induces persistent infection in some stallions as a virus-reservoir mechanism, EAV has likely developed strategies to avoid host antiviral factors by using its own viral proteins to modulate the cellular environment. With the advent of genomic tools, it has become possible to better study virus-host interactions at the molecular level. In particular, a variety of new "genomic and proteomic" methodologies have been developed to identify and characterize host molecules that closely interact with viruses during their life cycles. Thus, the "genomics revolution" has provided high-throughput tools with which to study complex virus-host interactions and, further, to provide information that will facilitate vaccine development and the design of efficacious therapeutic drugs.

It is abundantly clear that host genetic polymorphisms can affect microbial pathogenesis in animals. However, most host-pathogen interactions are complex and affected by several host genetic determinants. Until recently, emphasis was placed exclusively on identifying the viral factors affecting EVA pathogenesis, with no attention to the potential effect of host genetics on disease outcome. A high-quality draft of the genome of the horse (*Equus caballus*) was published recently ([@bib1350]), and the 55K equine single nucleotide polymorphisms (SNPs) chip was made available soon thereafter (Illumina Equine SNP50 chip, Illumina Inc, San Diego, CA). SNPs are variations of a single base-pair in the host\'s DNA; they are now used as genetic markers to identify chromosome regions associated with hereditary aspects of susceptibility to human or animal diseases ([@bib0225], [@bib0255], [@bib0575], [@bib1155]). The availability of the equine SNP chip provides a means of investigating genetic aspects of common horse diseases that was not previously possible.

5.5. Host factors {#sec0095}
-----------------

Recent studies have demonstrated that the clinical outcome of EAV infection is determined by host genetic factors. Specifically, based on the *in vitro* susceptibility of CD3^+^ T lymphocytes to EAV infection, horses can be segregated into susceptible and resistant phenotypic groups ([Fig. 10](#fig0050){ref-type="fig"} ; [@bib0495], [@bib0470]). Genome-wide association studies of these horses (GWAS) identified a common, genetically dominant haplotype associated with the *in vitro* susceptible phenotype in the region of ECA11 (49,572,804--49,643,932; [@bib0470]). Biological pathways analysis identified a variety of cellular genes within this region of ECA11 that encode proteins previously associated with virus attachment and entry, cytoskeletal organization, and NF-κB pathways. These cellular proteins are likely to be important in the pathogenesis of EVA infection in horses, so they clearly warrant further investigation to determine their precise roles ([@bib0470]). Furthermore, host cellular factors that are involved in formation of the replication complex and other membrane structures during virus replication, as well as cellular proteins involved in immune modulation during acute and persistent infection, should also be investigated using contemporary molecular biology techniques (*e.g.* siRNA, transcriptome analysis, *etc.*).Fig. 10Dual-color immunofluorescence flow cytometry analysis of T cells from carrier and seropositive non-carrier stallions following *in vitro* infection with EAV. (A) Carrier status was confirmed by repeatedly isolating EAV from semen over an extended period of time. (B) Non-carrier stallions were uninfected but seropositive to EAV following natural infection, not vaccination. Lymphocytes from each stallion that were labeled with both anti-CD3 and anti-nsp1 (12A4) MAbs are shown in the upper right quadrant of each dot plot. Note significant double labeling of lymphocytes from the carrier stallion but not the non-carrier stallion for both CD3 and EAV after *in vitro* infection.Modified from [@bib0475] with permission from the *Journal of Virology*.

Experimental EAV infection of horses with either the *in vitro* CD3^+^ T cell susceptibility or resistance phenotype showed a significant difference between the two groups in terms of proinflammatory and immunomodulatory cytokine mRNA expression. Of considerable importance, clinical signs of disease were enhanced in horses possessing the *in vitro* CD3^+^ T cell resistant phenotype ([@bib0480]). These studies provide direct evidence for a correlation in individual horses between their genotype and the extent of viral replication, occurrence and severity of clinical signs, and cytokine gene expression after experimental EAV infection. Furthermore, CD3^+^ T lymphocytes from EAV persistently infected (carrier) stallions are susceptible to *in vitro* EAV infection ([@bib0475]), whereas stallions that did not become long-term carriers after infection with EAV did not possess the CD3^+^ T lymphocyte-susceptible phenotype ([Fig. 10](#fig0050){ref-type="fig"}). Taken together, these data suggested that stallions with EAV susceptible CD3^+^ T lymphocytes are at a higher risk of becoming persistently infected as compared to stallions that lack this phenotype and GWAS analysis confirmed that five of seven proven carrier stallions had the dominant ECA11 haplotype previously associated with the CD3^+^ T lymphocyte susceptible phenotype. In summary, these data support the hypothesis that the long-term EAV carrier status in stallions is likely predisposed by specific host genetic factors.

6. Equine immune response to EAV {#sec0100}
================================

6.1. Innate immune response {#sec0105}
---------------------------

Natural EAV infection of horses occurs *via* either the respiratory tract following exposure to infective secretions/excretions, or the reproductive tract following venereal exposure ([@bib0040], [@bib1215]). Thus, it is the innate immune response of the mucosal lining of the respiratory and genital tracts that constitute the first line of defense that EAV encounters following natural exposure to the virus. There are few detailed studies that describe the innate immune response of horses to EAV, thus information pertaining to innate antiviral immunity is largely derived from the study of PRRSV and other viruses of the order *Nidovirales* ([@bib0135], [@bib0140], [@bib0380], [@bib0630], [@bib1130], [@bib1145]). However, preliminary studies have shown that EAV inhibits type I IFN production in infected cells and recent studies confirm that nsps 1, 2, and 11 are capable of inhibiting type I IFN activity. Of these three nsps, nsp1 has the strongest inhibitory effect on IFN synthesis. Clearly, failure to induce type I IFN in EAV infected cells may allow the virus to subvert the equine innate immune response. More recent work has further shown that the deubiquitinase function of the papain-like protease 2 suppresses the innate immune response in arterivirus-infected cells (reviewed under the section on nsp2; [@bib1330], [@bib1325]).

6.2. Antibody (humoral) immune response {#sec0110}
---------------------------------------

EAV infection in horses induces long-lasting immunity that likely protects against reinfection with most if not all strains of the virus ([@bib0070], [@bib0165], [@bib0340], [@bib0760], [@bib0775]). The humoral immune response to EAV is characterized by the development of both complement-fixing and virus-specific neutralizing (VN) antibodies ([@bib0400], [@bib0755]). Complement-fixing antibodies develop 1--2 weeks after infection, peak after 2--3 weeks, and steadily decline to disappear by 8 months, whereas VN antibodies are detected within 1--2 weeks after exposure, peak at 2--4 months, and persist 3 years or more ([@bib0100], [@bib0055], [@bib0110], [@bib0400], [@bib1215]). Foals born to immune mares are protected against clinical EVA by passive transfer of VN antibodies in the colostrum. VN antibodies appear a few hours after colostrum feeding, peak at 1 week of age, and gradually decline to extinction between 2 and 6, and rarely 7, months of age. The mean biological half-life of maternal antibodies in serum from foals is 32 days ([@bib0605]). Furthermore, passively acquired antibodies protected young foals that received colostrum from EAV seropositive mares against subsequent EAV infection, confirming the importance of antibodies in protection against the disease ([@bib0605], [@bib0765]). However, VN antibodies are not detected in foal sera prior to nursing, confirming that the passive immunity does not occur *via* the placenta *in utero* ([@bib0765]). Foals that received colostrum should be vaccinated after maternal antibodies disappear since these passive antibodies can neutralize the vaccine virus ([@bib0765]).

Appearance of neutralizing antibodies coincides with the disappearance of virus from the circulation of infected horses ([@bib0395], [@bib0755]). However, virus persists in the reproductive tract of the carrier stallion for a variable period despite the presence of high titers of VN antibodies in serum ([@bib1215]). Vaccination of horses with either modified-live or inactivated virus vaccines also can induce a robust VN antibody response ([@bib0420], [@bib0425], [@bib0775]).

GP5 expresses the major neutralization determinants of EAV and although considerable variation exists in the sequence of the GP5 protein of field strains of the virus, there is only one serotype of EAV and all strains evaluated thus far are neutralized by polyclonal antiserum raised against the prototype virulent Bucyrus strain ([@bib0085], [@bib0105], [@bib0080], [@bib0030], [@bib0070], [@bib0195], [@bib0315], [@bib0445], [@bib1420], [@bib1430]). However, field strains of EAV are frequently distinguished on the basis of differences in their neutralization phenotype with polyclonal antisera and monoclonal antibodies and, similarly, geographically and temporally distinct strains of EAV can differ in the severity of the clinical disease they induce and in their abortigenic potential ([@bib0035], [@bib0045], [@bib0800], [@bib0805], [@bib0860], [@bib0910], [@bib1215]). Most of the neutralization epitopes of EAV (with the exception of aa 49) are located in the variable region V1 (aa 61--121) of the GP5 protein ([@bib0080]). Studies using MAbs and reverse genetics have shown that aa changes at aa 61 (site B) and 67--90 (site C) of the GP5 protein influence the expression of conformational neutralizing epitopes and similar changes are likely to be responsible for antigenic variation among EAV field strains ([@bib0080], [@bib0030]). Therefore, it is likely that aa changes in the GP5 N-terminal ectodomain, especially if they occur during persistent infection in carrier stallions, contribute to the emergence of EAV strains with different neutralization phenotypes ([@bib0030]). Horses also produce non-neutralizing anti-GP5 antibodies in response to EAV infection or immunization with inactivated whole-virus vaccine ([@bib0200], [@bib1365]).

The humoral immune response to structural EAV proteins in naturally or experimentally infected horses varies widely with the infecting EAV strain, the interval after infection, and the individual horse ([@bib0540], [@bib0725], [@bib0880]). The variation in the antibody response to EAV structural proteins was also observed in horses immunized with the modified live EAV vaccine ([@bib0540], [@bib0725]). Non-neutralizing antibodies that recognize the N and M proteins are detected as early as 14 days post-infection (dpi) and can last at least 145 days in sequential sera from horses experimentally infected with EAV ([@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0195], [@bib0540], [@bib0640], [@bib0725], [@bib1365]). Of the EAV structural proteins, the M protein is the most consistently recognized by immunoblotting or ELISA analysis of convalescent sera from EAV-infected horses ([@bib0540], [@bib0725]), whereas responses to the N and GP5 proteins are more variable. The C-terminal domain of the M protein (aa 88--162) contains linear epitopes and is recognized by all EAV-specific horse antisera ([@bib0620]). The GP2 protein was poorly recognized by equine antisera ([@bib0725]). The ORF7 encoding the N protein is highly conserved among strains ([@bib0215]). The portion between aa 1 and 69 of the N protein has been identified as the most immunoreactive region. Sera from persistently infected stallions consistently recognized GP5, N, and M proteins. In contrast, most convalescent sera from mares, geldings, and stallions that did not become carriers after exposure to EAV recognized the carboxy-terminal region of the M protein ([@bib0725]). Sera from horses experimentally or persistently infected with EAV strongly reacted with nsp2, nsp4, nsp5 and nsp12, whereas horses vaccinated with the MLV vaccine did not react with nsp5 and reacted only weakly with nsp4 ([@bib0485]).

6.3. Cell-mediated immune response {#sec0115}
----------------------------------

The cell-mediated immune response (CMI) to EAV is poorly characterized. [@bib0180] described EAV-specific cytotoxic T lymphocyte (CTL) responses using peripheral blood mononuclear cells (PBMCs) from convalescent EAV-infected (experimental) ponies. The data showed that cytotoxicity induced by EAV-stimulated PBMCs was virus-specific, genetically restricted, and mediated by CD8^+^ T cells, and that EAV-specific CTL precursors persist for at least 1 year after infection. There are no other comprehensive studies to date that describe CMI response to the MLV vaccine or to any other strains of EAV in horses, nor any published studies that definitively identify the specific viral protein(s) targeted by the CTL response of EAV-infected horses.

7. Genetic diversity, molecular epidemiology and evolution of EAV {#sec0120}
=================================================================

Original phylogenetic analyses based on ORF5 clustered field strains of EAV into two distinct clades, reflecting their origins in either North American (NA) or Europe (EU) ([@bib0105], [@bib0590], [@bib1100]). The EAV isolates in the European group could be further divided into two subgroups, European subgroup-1 (EU-1) and European subgroup-2 (EU-2). Comparison of sequence data from individual EU and NA isolates showed movement of viruses between the two continents from movement/transport of carrier stallions and/or their semen ([@bib0105], [@bib0590], [@bib0830], [@bib1150], [@bib1430]). However, EAV field isolates from North America and Europe are closely related and differ only by 15% at the nucleotide level. The major nucleotide and amino acid differences between NA and EU EAV strains occur in the nsp2-encoding portion of ORF 1a, as well as in ORFs 3 and 5 that encode the GP3 and GP5 envelope proteins respectively ([@bib0070], [@bib0560], [@bib0830], [@bib0965], [@bib1430]). Comparative nucleotide and amino acid full-length sequence analysis of EAV strains ([Table 1](#tbl0005){ref-type="table"}) clearly demonstrated that there is considerable variation in nsp2, with aa substitutions being concentrated in the central segment (aa 388--496) of the protein. The biological significance of this extensive variation of nsp2 among field strains of EAV remains uncertain.

During persistent infection of carrier stallions, EAV infection is restricted to the reproductive tract and is localized principally in the ampulla of the vas deferens ([@bib0785], [@bib1215], [@bib1225]). Notwithstanding high neutralizing antibody titers in their serum, carrier stallions continuously shed infectious virus in their semen. Carrier stallions are the essential virus reservoir that maintains and perpetuates EAV in the equine population between breeding seasons. Most importantly, the carrier stallion clearly is responsible for generating the genetic heterogeneity that distinguishes individual field strains of EAV ([@bib0545], [@bib0555]). Sequence analyses of the variable ORF5 gene of strains of EAV sequentially present in the semen of carrier stallions showed that EAV behaves as a quasispecies (population of genetically related viral variants) during persistent infection, leading to both genetic and phenotypic divergence of the virus ([@bib0045], [@bib0050], [@bib0555], [@bib0830], [@bib1435], [@bib1430]). Outbreaks of EVA result from the emergence and spread of specific variants of EAV that are present in the quasispecies virus population in the semen of individual carrier stallions; however, the mechanisms involved in selection and emergence of virulent viral variants remain unclear. It is also clear that novel variants with distinct neutralization phenotypes arise during persistent infection of carrier stallions, and that the altered neutralization phenotype of these variants correlates with amino acid changes in specific regions of the GP5 envelope glycoprotein ([@bib0080], [@bib0035], [@bib0045], [@bib0030], [@bib0070], [@bib0555]). However, despite this diversity all of the variants that arise in the course of persistent infection of carrier stallions are neutralized by high-titer polyclonal equine sera, which suggests that immune evasion is not responsible for the establishment of persistent EAV infection of carrier stallions. There also is no evidence to date that positive selective pressures, which would be expected if there was immune-selection, are responsible for establishment of persistent EAV infection of stallions ([@bib0050], [@bib0555]).

The recent advent of molecular techniques has helped greatly to increase understanding of the epidemiology of EAV infection and occurrence of outbreaks of EVA. For example, investigation of an extensive outbreak of EVA on a breeding farm showed that a single virus variant present in the semen of a carrier stallion was selected and then efficiently transmitted by aerosol among other horses on the farm ([@bib0045]). Thus, it appears that the considerable genetic heterogeneity afforded by the viral quasispecies likely facilitates persistence of EAV in the reproductive tract of carrier stallions. However, only some members (variants) within the quasispecies appear to be capable of efficient aerosol transmission to other horses, perhaps because of an enhanced ability to replicate within the respiratory tract. The individual strains of EAV that circulated during this restricted EVA outbreak were genetically stable during repeated horizontal and vertical passage in horses, unlike the diverse, quasispecies virus population contained in the semen of the carrier stallions on the farm. In contrast, the 2006--2007 multistate EVA outbreak in the US spanned a period of more than 10 months of active circulation of EAV in horses of several breeds on multiple farms in different states. Characterization of viruses isolated during this extensive and protracted outbreak showed that genomic variability increased with extensive horizontal and vertical virus transmission over an extended time period ([@bib1420], [@bib1430]). Moreover, one of the isolates from an aborted fetus had a very distinct neutralization phenotype and was not neutralized by monoclonal antibodies that neutralized the other EAV isolates from the outbreak. Similarly this virus was neutralized to a significantly lower titer by polyclonal antisera as compared to other isolates. In summary, genetic divergence of EAV occurs in the course of persistent infection of the reproductive tract of carrier stallions, leading to the emergence of novel strains of EAV, and likely compensating for the minimal virus diversity that is generated during small/restricted outbreaks of EVA when the virus can be transmitted by respiratory and/or venereal routes. Therefore, the persistently infected carrier stallion serves as the natural reservoir that harbors EAV between breeding seasons and also provides the environment in which genetic diversification of the virus occurs.

8. Diagnosis of EAV infection {#sec0125}
=============================

Confirmation of a diagnosis of EVA currently is based on virus detection by either virus isolation (VI) or polymerase chain reaction (PCR), and/or serological demonstration of rising neutralizing antibody titers (4-fold or greater) in paired serum samples taken at a 21- to 28-day interval using the virus neutralization test (VNT). The VNT is the principal serological assay used to detect evidence of EAV infection by most laboratories around the world, and it continues to be the current World Organization for Animal Health (OIE) prescribed standard test for EVA ([@bib0015]). Several laboratories have developed and evaluated enzyme-linked immunosorbent assays (ELISAs) to detect antibodies to EAV using whole virus, synthetic peptides, or recombinant viral proteins (*e.g.* GP5, M, and N) as antigens ([@bib0180], [@bib0245], [@bib0360], [@bib0540], [@bib0660], [@bib0880], [@bib1110], [@bib1355]). Various studies have shown that the source of antigen as well as the sera evaluated can markedly influence the results obtained with EAV protein specific ELISAs and competitive ELISA. Recently, a competitive blocking ELISA using a GP5-specific monoclonal antibody has been described and this assay reportedly has very high specificity and sensitivity ([@bib0020]). However, none of these ELISAs or recently described microsphere immunoassay (Luminex) has yet been shown to be of equivalent sensitivity and specificity to the VNT ([@bib0360], [@bib0490]). Thus, VNT assay remains the "gold standard" for detection of serum antibodies to EAV.

EAV can be isolated in cell cultures, typically RK-13 cells ([@bib0015]), from nasal swabs or anticoagulated blood collected from adult horses with signs of EVA, or the tissues of aborted equine fetuses (lung, spleen, lymph nodes, and placenta). Carrier stallions are first identified by serology as they are always seropositive, and persistent infection is confirmed by VI from semen in cell culture or by test-breeding seronegative mares which are monitored for seroconversion to EAV after breeding.

Several reverse transcriptase-polymerase chain reaction (RT-PCR) assays (*e.g.* standard RT-PCR, RT-nested PCR \[RT-nPCR\] and real-time RT-PCR \[rRT-PCR\]) for detection of EAV nucleic acids in cell culture supernatants and clinical specimens have been developed ([@bib0065], [@bib0210], [@bib0440], [@bib0960], [@bib0985], [@bib1090], [@bib1370]). These assays target different genes (ORFs 1b, 3, 4, 5, 6, and 7), and their sensitivity and specificity vary considerably. The sensitivity of RT-PCR-based assays is significantly increased by using either RT-nPCR that incorporates two primer pairs specific for ORF 1b or real-time TaqMan RT-PCR that uses primers and a probe specific for a highly conserved region of ORF7 ([@bib0065], [@bib0710], [@bib0835]). Although VI is currently the OIE-approved gold standard for the detection of EAV in semen and is the prescribed test for international trade, it has been demonstrated that at least one published rRT-PCR assay has equal or even higher sensitivity than VI for the detection of EAV nucleic acid in semen samples from carrier stallions ([@bib0835]). Very clearly, rRT-PCR has significant advantages over VI in terms of reproducibility between laboratories, ease and speed of completion, and cost, thus it is logical that the most accurate rRT-PCR assay would replace VI as the prescribed test for international trade. Histopathologic examination coupled with immunohistochemical staining is also useful for diagnosis of abortion in particular ([@bib0290], [@bib0295], [@bib0585], [@bib0705], [@bib1160]), as are standard RT-PCR or rRT-PCR assays.

9. Vaccines {#sec0130}
===========

The modified live virus (MLV) vaccine, ARVAC^®^ (Fort Dodge Animal Health, Fort Dodge, IA \[now Zoetis Animal Health, Kalamazoo, MI\]) is currently used widely in North America, whereas an adjuvanted killed virus vaccine, ARTERVAC^®^, is approved for use in several European countries. While the current MLV vaccine against EVA is safe and believed to be efficacious, the vaccine is not recommended by the manufacturer for use in pregnant mares, especially during the last 2 months of gestation, or in foals less than 6 weeks of age unless they are at high risk of natural exposure ([@bib0070], [@bib0160], [@bib1215]). Furthermore, horses that are vaccinated with the MLV vaccine cannot be serologically distinguished from naturally infected animals. Vaccination studies using the MLV showed that a single dose of vaccine stimulates only low, transient levels of VN antibodies; however, additional doses boost antibody levels with titers maintained for at least 9--12 months ([@bib0405], [@bib0825], [@bib1210]). Similarly, a formalin-inactivated vaccine without adjuvant was shown to induce high titers of VN antibodies after repeated doses ([@bib0420], [@bib0425], [@bib0415], [@bib0410]).

A stable full-length cDNA clone of the current MLV vaccine strain of EAV has been recently developed ([@bib1410]). RNA transcripts generated from this plasmid (pEAVrMLV) were infectious upon transfection into mammalian cells and the resultant recombinant virus (rMLV) had 100% nucleotide identity to the parental MLV vaccine strain of EAV. A single silent nucleotide substitution was introduced into the nucleocapsid gene (pEAVrMLVB), enabling the cloned vaccine virus (rMLVB) to be distinguished from the parental MLV vaccine as well as other field and laboratory strains of EAV using an allelic discrimination rRT-PCR assay. *In vivo* studies confirm that the cloned vaccine virus is safe and induces high titers of neutralizing antibodies against EAV in experimentally immunized horses. However, when challenged with the heterologous KY84 strain of EAV, the rMLVB vaccine virus protected immunized horses in terms of reducing the magnitude and duration of viremia and virus shedding, but did not totally prevent clinical signs of EVA, although these were reduced in severity. While it is believed there is only one known serotype of EAV, field strains clearly differ in their neutralization phenotype ([@bib0075], [@bib0080], [@bib0030], [@bib0720], [@bib0830], [@bib1435], [@bib1430]). It has been shown previously that the serum from horses vaccinated with the MLV vaccine strain neutralizes some EAV field strains such as the KY84 strain to a lower titer (≤1:8--1:64) ([@bib0080], [@bib0030], [@bib0465], [@bib1430]). This likely explains why rMLVB vaccinated horses were not fully protected against EVA following challenge with the heterologous KY84 strain, and also further confirms the importance of high titer neutralizing antibodies (≥1:64) in protecting against the clinical signs of EAV infection ([@bib0400], [@bib1205], [@bib1230]). These recent data also emphasize the need for additional in-depth cross-neutralization studies using more recent EAV isolates representing all three phylogenetic clades of EAV (North American and two European \[EU-1 and EU-2\]).

The infectious cDNA clone of the MLV vaccine strain of EAV could potentially be used to design and to develop more broadly protective recombinant MLV vaccines by systematically incorporating key neutralization epitopes from various EAV isolates of significantly distinct neutralization phenotypes. Furthermore, the vaccine clone pEAVrMLVB could be further manipulated to improve the vaccine efficacy as well as to develop a marker vaccine for serological differentiation of EAV naturally infected from vaccinated animals.

Other experimental EAV vaccine constructs using recombinant DNA technology have been described, including a subunit vaccine, a Venezuelan equine encephalitis \[VEE\] replicon particle (VRP)-based vaccine, an infectious clone-based live-marker vaccine, and a DNA vaccine (reviewed in [@bib0070]). The N-terminal ectodomain (aa 18--122) of GP5 expressed in bacterial cells induced higher neutralizing antibody titers compared to other GP5 polypeptides in ponies ([@bib0175]). [@bib0055] demonstrated that alphavirus VRP co-expressing GP5/M from the VBS strain of EAV can induce complete protective immunity in horses to challenge with the heterologous KY84 strain of EAV. DNA vaccination using genes encoding the GP5 and N proteins of EAV has been tested in mice ([@bib1235]). The highest VN antibodies were induced in animals vaccinated with plasmid DNA encoding ORF5 ([@bib1235]). Later, a DNA vaccine expressing ORFs 2, 5, and 7 in combination with equine interleukin-2 was evaluated in horses ([@bib0435]). After the initial immunization, three boosters were administered at 2-week intervals. All vaccinated horses developed high VN antibody titers regardless of age and VN antibodies were still detectable over a year later ([@bib0435]). [@bib0180] described creation of a candidate live marker vaccine for EAV by deletion of the major neutralization domain (aa 66--112) in the GP5 protein in an infectious cDNA clone. Similarly, the EAV030 cDNA clone has been used to develop disabled infectious single-cycle (DISC) mutants using complementing cell lines expressing minor structural proteins (GP2 \[formally G~S~\], GP3, and GP4) ([@bib1405]). However, vaccines based on recombinant DNA technology have not yet been adopted for commercial use.

10. Antivirals and other therapeutics {#sec0135}
=====================================

The antiviral potential of phosphorodiamidate morpholino oligomers (PMOs) directed against EAV has been evaluated previously ([@bib1275], [@bib1420]). PMOs are single-stranded DNA analogs ([@bib1140]), usually 20--25 bases in length, water-soluble, and nuclease-resistant ([@bib1135]). PMOs can base pair with a complementary RNA target sequence and form a steric blockade to interfere with gene expression, particularly with translation of the genome ([@bib1115], [@bib1135]). Peptide-conjugation to the PMO (P-PMO) greatly improves delivery of PMO into cells ([@bib0005]). The 5′ UTR of the EAV genome contains the most sensitive targets for inhibition with P-PMOs ([@bib1275]). Treatment with an antisense P-PMO targeting the EAV 5′-terminus at a concentration of 5--10 μM eliminated the virus from persistently infected HeLa cells ([@bib1420]). However, the efficacy of P-PMO against EAV infection *in vivo* remains to be evaluated. Furthermore, horse cells transfected with small interfering RNA (siRNAs) targeting the ORF1ab prior to infection with EAV markedly reduced subsequent virus titers in the cell cultures ([@bib0565]). In other studies, it was reported that horse cells treated with 100 U/ml recombinant equine IFN-γ were protected against infection with 100 TCID~50~ of infectious EAV ([@bib0990]). Several carbohydrate-binding agents, such as plant and non-plant lectins, have also been shown to have antiviral activities against nidoviruses ([@bib1280]). Although the antiviral effects shown *in vitro* are promising, *in vivo* application of antiviral agents and therapy may be limited due to the large mass of horses and the inherent costs involved.

The EAV carrier state is clearly testosterone-dependent, and transient suppression of testosterone production in carrier stallions may offer therapeutic promise in the elimination of EAV infection ([@bib0455], [@bib0580], [@bib0700], [@bib1215]). There are preliminary data to support the strategy that GnRH (Gonadotropin-releasing hormone) vaccines or antagonists can temporarily limit the shedding of the virus in the semen of carrier stallions.

11. Summary and perspectives {#sec0140}
============================

There has been significant recent progress in understanding the molecular biology of EAV and the pathogenesis of its infection in horses. The application of cutting edge molecular biology techniques along with development of reverse genetic systems to manipulate the viral genome has facilitated these advancements. EAV has been used as a model system with which to study the replication and transcription of nidoviruses, in part because of its small genome size and similar genome organization and replication strategy to coronaviruses and toroviruses. However, the exact site and location of EAV RNA synthesis and RNA-synthesizing enzyme complexes in infected cells remains to be identified. Furthermore, the subcellular localization of the individual EAV nsps and the various membrane structures they appear to induce warrants further investigation.

Although, the key viral determinants of virulence and persistence have been identified using laboratory strains of EAV, this data should be carefully extrapolated to better identify how virulent virus strains emerge during persistent infection in stallions. Similarly, most field strains of EAV are naturally attenuated and the amino acid changes involved in attenuation of these viruses may not be the same as those in vaccine viruses. Furthermore, the amino acid substitutions that are associated with the establishment of persistent infection in HeLa cells may differ from those involved in the establishment of persistent infection in the stallion. Thus, further whole genome sequence analysis of the quasispecies populations of field strains of EAV from disease outbreaks and from the semen of persistently infected stallions is critical to further refine the viral determinants of virulence and persistence.

Future development of efficacious vaccines that will engender broad heterotypic immunity to all strains of EAV will require ongoing comparative sequence analysis of ORF5 of field isolates of the virus from around the world. Recent studies indicate that the existing vaccines may not induce complete protection against all field strains of EAV. Logically, future vaccines will be developed utilizing recombinant DNA technology, such as the use of infectious clones as a stable genetic background to develop marker (DIVA) vaccines that distinguish naturally infected horses from vaccinated ones.

The equine innate and cellular immune response to EAV infection has also not yet been fully investigated. For example, the viral proteins that express CTL epitopes are yet to be identified and characterized. Similarly, aspects of the pathogenesis of EAV infection of horses require further characterization. Notably, the EAV cellular receptor is yet to be identified, and mechanisms of virus attachment and entry have yet to be elucidated. The recent availability of contemporary genomic techniques will also facilitate the identification of the cellular factors and pathways associated with assembly of EAV particles in infected cells. Of particular importance is the fact that neither the location of EAV persistence in the male reproductive tract nor the mechanisms of persistence have been examined in depth using contemporary molecular biology techniques. Such studies are prerequisite to the logical design and development of antiviral drugs to clear virus from the reproductive tract of carrier stallions. It has been shown that establishment of the carrier state may correlate with susceptibility of CD3^+^ T cell populations to infection with EAV, which is associated with a genetically dominant haplotype on ECA11. Characterization of the genetic basis of the EAV carrier state in stallions could lead to development of genetic tests capable of identifying stallions that are at most risk of becoming long-term carriers following EAV exposure and so offer important new insights into effective treatment options.

Current OIE (World Organization for Animal Health) approved diagnostic assays are largely based on outdated "classical virology" techniques that should quickly be replaced with more appropriate contemporary assays. Specifically, it has been shown that at least one rRT-PCR assay has equal or higher sensitivity than VI in RK-13 cells for the detection of EAV nucleic acid in semen samples. The rRT-PCR has enormous advantage in terms of assay standardization between laboratories as well as in terms of operational time and cost and should be considered equivalent or an alternative to VI for EAV detection in samples of raw semen. Similarly, the VN assay remains the OIE prescribed regulatory test for serologic detection of EAV infection of the horse, despite the fact that this assay is expensive, labor-intensive, and time-consuming to perform. Furthermore, results of the VN assay can vary markedly among laboratories when insufficient attention is paid to standardization of both test reagents and procedures, thus there is an urgent need to develop highly specific and sensitive ELISA or microsphere immunoassay (Luminex) for the detection of EAV antibodies in serum samples. Incorporation of the immunogenic nsps in such an assay is likely to improve both its sensitivity and specificity.
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